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Abstract 
Drug delivery systems have great importance for medical application. There have been wide 
ranging studies on drug delivery systems up to date. Among them, the fabrication of nano-size 
drug delivery systems and utilizing them for the effective and controlled delivery of drugs is 
an emerging and promising field of research. Various studies on drug nanocarriers have been 
reported such as electrospun nanofibres and nanoparticles; however the main drawback of 
nearly all is that they lack the control over the release profile of the drug. The burst release of 
drug is the main issue reported seen in almost all cases.  
The purpose of this work was to develop composite biodegradable nanofibres fabricated using 
the electrospinning technique with different chemical and physical approaches to slow down 
the fast burst release and control the release profile. This thesis exploits electrospun 
biodegradable nanofibres as the main carrier of drug/nanoparticles complexes and drug-conjugated 
polymers to obtain sustained release of drug. To achieve this, mesoporous silica nanoparticles 
(MSN) acting as a nano sized vehicle as a drug delivery system were first investigated. Then, the 
adsorption of the drug into mesoporous structure was fabricated and characterized. The drug loaded 
nanoparticles were confined to the core section of core-shell nanofibres by means of co-axial 
electrospinning. This method provided a reduction in burst release compared to regular drug-
nanofibres and a sustained release. In the next stage, a model drug was covalently bound to the 
silica nanoparticles via a cleavable bond. In the first two experiments the MSN was used as 
nanocarrier of levofloxacin (LVF). LVF-MSN complexes were prepared using different 
approaches. In the first approach, LVF was physically adsorbed into the porous structure of the 
MSN. The LVF-MSN complex was then confined into the core section of core-shell PCL 
nanofibres. In the second approach, LVF was covalently bound to MSN via a cleavable bond 
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which can be hydrolysed in release buffered solution. LVF-MSN conjugated complexes were 
then blended with PCL and composite nanofibres fabricated by electrospinning techniques.   
In the final experiment, polyvinyl alcohol (PVA) was used as the main polymer matrix. The 
purpose of this experiment was to achieve sustained release of drug from a fast dissolving polymer. 
To achieve this goal, chitosan (CS) as a naturally derived polymer, was used as main carrier of 
LVF. LVF was covalently bound to the chitosan via a cleavable bond. The conjugated LVF-CS 
was blended into a PVA solution and electrospun.   
In vitro drug release profiles were measured in all cases. The research confirmed that release 
profiles can be affected by chemical and physical factors. First, the core-shell structure of 
nanofibres can reduce burst release behaviour. This can be further reduced by employing LVF 
encapsulated MSN. Second, cleavable bonds between LVF and carriers played a significant 
role in reducing the burst release behaviour; where LVF was released first by hydrolysis of the 
cleavable bonds between LVF and carriers, and then from the polymer matrix.  
The results indicated that burst release of the drug significantly reduced in all studies and the 
release profiles of drug were all slowed. The physical and chemical approaches used in the 
thesis to fabricate drug loaded composite nanofibres showed slow release of LVF with 
sustained release over a sustained period of time.  
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LITERATURE REVIEW 
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1.1  Drug Delivery Systems  
Drug delivery systems (DDS) are designed to consistently introduce therapeutic agents into the 
body at a required dose level and rate. The first development  appeared in the 1960s when  
Folkman [1] circulated rabbit blood inside a silicone rubber arteriovenous fistula and 
discovered that if he exposed the tubing to anaesthetic gases on the outside, the rabbits would 
fall asleep. It was then proposed that short, sealed segments of such tubing containing a drug 
could be implanted and could become a constant rate drug delivery device [2]. Drug delivery 
systems are designed to alter the pharmacokinetics and distribution of associated drugs to 
function as drug carriers (i.e., as sustained release systems). Pharmacological properties of 
conventional drugs can be improved through the use of drug delivery systems. Drug delivery 
systems are expected to create novel therapeutics for successful treatment due their advantages. 
The main advantages of drug delivery systems include enhanced drug solubility, reduced 
toxicity, protecting the drug from undergoing rapid decomposition and degradation and 
reduced side effects in non-target tissues. Table 1-1 shows examples of the problems faced by 
free drug administration that can be improved by the use of drug delivery systems [3].  
The concept of drug delivery and controlled drug delivery devices has been considered by the 
chemist Zaffaroni in California USA. He founded a company in the late 1960s focused on the 
concept of controlled drug delivery [4]. This term is used to define  the encapsulation or 
attachment of drugs to enhanced carriers, which alter their localization in the body and their 
uptake into different tissues [5]. Subsequently, controlled release systems for drugs have been 
widely explored due to their advantages such as improving therapeutic efficiency by delivering 
the drug at a controlled release rate consequently overcoming adverse side effects [6, 7].   
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Table 1-1 Effects of drug delivery systems on drugs and their therapeutic implications [3] 
Problem Implication Effect of DDS 
Poor solubility 
A convenient pharmaceutical 
format is difficult to achieve, due 
to the possibility of precipitation of 
hydrophobic drugs 
DDS provide both hydrophilic 
and hydrophobic environments, 
enhancing drug solubility 
Tissue damage due to 
the leakage of the 
drug   
Unintentional leakage of cytotoxic 
drugs lead to tissue damage 
Regulated drug release from the 
DDS can reduce/eliminate tissue 
damage on accidental 
extravasations 
Fast collapse of the 
drug in vivo 
Loss of activity of the drug follows 
administration, e.g., loss of activity 
of drug at certain pH 
Protected drug from premature 
degradation and functions as a 
sustained release system 
Unfavourable 
pharmacokinetics 
(PK) 
Drug is cleared too rapidly, by the 
kidney, for example, requiring high 
doses or continuous infusion 
DDS can substantially alter the 
PK of the drug and reduce 
clearance. Rapid renal clearance 
of small molecules is avoided 
Poor biodistribution 
Drugs that have widespread 
distribution in the body can affect 
normal tissues, resulting in dose-
limiting side effects 
The particulate nature of DDS 
lowers the volume of distribution 
and helps to reduce side effects 
in non-target tissues 
Lack of selectivity 
for target tissues 
Distribution of the drug to normal 
tissues leads to side effects. 
Adverse therapeutic effects due to 
low concentrations of drugs in 
target tissues 
DDS can increase drug 
concentrations in target tissues 
such as tumors 
 
Various advantages of controlled drug release systems compared to other methods of drug 
administration have been reported [8]. These advantages include reducing the side effects of 
systemic administration by local administration from a controlled release system, improved 
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drug administration in areas where good medical supervision is not available, continuous 
sustained release of small amounts of drug instead of painful large doses, and improvement of 
patient compliance. In order to reach these goals, several factors should be considered in a 
controlled drug delivery system; such as delivery vehicle materials, the drug properties, route 
of administration, mechanism of drug release, ability of targeting, and biocompatibility (Figure 
1-1) [9].  
 
Figure 1-1 Design requirements for drug delivery systems 
In the past few decades a variety of biocompatible drug delivery systems have been explored 
with enhanced properties for encapsulation and release kinetics. It was demonstrated that when 
a pharmaceutical agent is encapsulated within, or attached to, a carrier, drug efficacy and safety 
may be improved [10].  The concept encouraged active and intensive researches for the design 
of biodegradable materials as drug delivery systems. Recent efforts have led to the 
development of a new approach in the field of controlled drug delivery with the creation of 
nano-sized biodegradable polymeric drug delivery systems [11]. The key requirement of a 
controlled drug release system is to allow sustained release of the active agent continuously 
over an extended period of time to achieve a consistent therapeutic drug release profile which 
Duration 
of delivery 
Route of 
administration 
Drug 
Properties 
Mechanism of 
drug release 
Biocompatibility 
Nature of delivery Ability to 
targeting 
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results in extended therapeutic advantages over the duration of action by reducing problems 
associated with multiple  dosing [12].  
 The Economics of Drug Delivery Systems 
Drug delivery technology can bring both therapeutic and commercial value to healthcare 
products. Major pharmaceutical companies have recently started losing their market share to 
their competitors after their patents expired. Therefore they have started to recognize the 
importance of drug delivery systems. The drug delivery technology market is segmented on 
the basis of route of administration into different categories such as oral, pulmonary, 
transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal [13]. The value 
of the global market was $142.5 billion in 2012; with North America as the largest market, 
followed by Europe, and Asia. The market is expected to rise at a compound annual growth 
rate of 5% and reach nearly $175 billion by 2016. Key players in the market are 3M  (U.S.), 
Alkermes (Ireland), Aptalis Pharma, Inc. (U.S.), Baxter International, Inc. (U.S.), Becton 
Dickinson & Co. (U.S.), Catalent Pharma Solutions (U.S.),  Dow Chemical Company (U.S.), 
Endo Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Nektar Therapeutics (U.S.), 
SkyePharma PLC (U.K.), and Ypsomed Holding AG (Switzerland) [14]. The following are 
some examples in the market now. The Atridox® is a controlled-release product for delivering 
tetracycline antibiotics to the infected tooth pockets for a period of 7 days. ARESTIN® contains 
tetracycline antibiotic loaded materials used for treating gum problems that occur after certain 
dental procedures. Estrasorb™ is designed to deliver estradiol to the blood circulation by 
absorbing through the skin and enters into the bloodstream. 
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1.2 Impact of Nanotechnology 
Nanotechnology is about the engineering and manufacturing of materials at the molecular 
scale. It refers to a structure with a size of generally 1-100 nanometers (nm) in at least one 
dimension. Nanotechnology, regardless of the mentioned size restriction, commonly refers to 
structures that are up to several hundred nanometers and generally less than a micrometer  (10-
6meter) in size.  
The role of nanotechnology in the application of drug delivery is widely expected to transform 
the landscape of pharmaceutical and biotechnology industries in the near future [15]. Drug 
delivery is one of the most demanding areas in nanotechnology with  engineering of nano-sized 
material specially for cancer therapies and diagnostics [16]. The development of nanocarriers 
may have an important role in adding new therapeutic achievements to the drug delivery 
industry and disease therapy. It is expected to achieve improved delivery of water insoluble 
drugs, targeted delivery of drugs in to tissues, delivery of large macromolecule drugs to 
intracellular sites of action, simultaneous delivery of two or more therapeutic agents for 
combination therapy and improved in vivo efficacy of a therapeutic agent [16].  
The first nanosize drug delivery systems were lipid based carriers, which were introduced in 
the 1960s and were later known as liposomes [17]. Subsequently, a variety of other synthetic 
and natural biomaterials were developed as drug delivery systems. Various nanomaterials such 
as nanoparticles and nanofibres were designed with abilities to encapsulate and release the 
drugs to targeted tissue [18]. The field has grown rapidly.  A wide range of drug delivery 
nanocarriers have now been investigated such as liposomes or lipid-based materials [19, 20], 
biocompatible polymeric micro- and nanoparticles [21-25] and nanofibres [26-29]. 
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1.3 Recent Material Designs for Drug Delivery Systems 
Design and synthesis of various biocompatible materials has driven the progress of drug 
delivery systems over the past few decades. The field has quickly grown since to include a 
wide variety of drug delivery nanocarriers such as liposomes (lipid-based materials) [30, 31], 
biodegradable polymeric nanocarriers including block copolymers and polymer-drug 
conjugates [23-25, 32]. Liposome has been the most successful candidate in clinical 
applications. Most of food and drug administration (FDA) approved drug delivery systems in 
the market are based on liposome or lipid-based material. Moreover, polymer–drug conjugates, 
especially those conjugated with polyethylene glycol (PEG), is now a standard method to 
increase circulation and bioavailability of bio-macromolecules such as antibodies. A summary 
of FDA approved systems is listed in Table 1-2. 
Liposomes are composed of a lipid bilayer separating an aqueous internal compartment from 
the bulk aqueous phase. Micelles are closed lipid monolayer with a fatty acid core and polar 
surface, or polar core with fatty acids on the surface (Figure 1-2). They are small vehicles with 
a spherical shape that can be produced from cholesterols, non-toxic surfactants, lipids, 
glycolipids, long chain fatty acids and even membrane proteins. They can be loaded with a 
great variety of molecules such as small drug molecules, proteins and even plasmids. 
Liposomes can be formulated and processed to different size and compositions. Many anti-
tumor and antifungal drugs loaded into liposomes have been commercialized to date (Table 1-
2). 
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Table 1-2 FDA approved drug delivery systems in the market 
Products 
Approval 
Year  Technology Indication 
L
ip
o
so
m
e 
&
 m
ic
el
le
 Doxil 1995 
PEGylated liposomal 
doxorubicin 
Various types of cancer 
Daunoxome 1996 Liposomal daunorubicin Advanced HIV-associated  
Ambisome 1997 Liposomal amphotericin B Fungal infections 
Depocyt 1999 Liposomal cytarabine Lymphomatous meningitis 
Visudyne 2000 Liposomal verteporfin Age-related macular degeneration 
Estrasorb 2003 Estradiol micellar nanoparticles 
Moderate to severe vasomotor 
symptoms of menopause 
DepoDur 2004 Liposomal morphine sulfate Postoperative pain 
P
o
ly
m
er
–
d
ru
g
 c
o
n
ju
g
at
e 
Oncaspar 1994 PEGylated L-asparaginase Acute lymphoblastic leukemia 
PEG-intron 2001 PEGylated interferon alfa-2b Chronic hepatitis C 
PEG-ASYS 2002 PEGylated interferon alfa-2a Chronic hepatitis C & B 
Neulasta 2002 PEGylated granulocyte colony Neutropenia 
Somavert 2003 PEGylated  Acromegaly 
Macugen 2004 PEGylated anti-VEGF aptamer Age-related macular degeneration 
Mircera 2007 
PEGylated erythropoetin 
receptor activators 
Anaemia associated with chronic 
kidney disease 
Cimzia 2008 
PEGylated tumor necrosis factor 
alpha inhibitor 
Crohn's disease 
Krystexxa 2010 PEGylated urate oxidase Gout 
Omontys 2012 PEGylated peginesatide Chronic kidney disease 
B
io
d
eg
ra
d
ab
le
 m
at
er
ia
ls
 
Zoladex 1989 PLGA/goserelin acetate Prostate and breast cancer 
Lupron 
Depot 
1989 PLGA/leuprolide acetate Prostate cancer and endometriosis 
Gliadel 1996 Polifeprosan /carmustine 
High-grade & recurrent 
glioblastoma multiforme 
Sandostatin 
LAR 
1998 PLGA-glucose/Acetate Acromegaly 
Atridox 1998 PLA/doxycycline hyclate Periodontal disease 
Nutropin 
depot 
1999 
PLGA/recombinant human 
growth hormone 
Growth hormone deficiency 
Trelstar 2000 PLGA/triptorelin pamoatea Advanced prostate cancer 
Arestin 2001 PLGA/minocycline Adult periodontitis 
Eligard 2002 PLGA/leuprolide acetate Advanced prostate cancer 
Risperdal 
Consta 
2003 PLGA/risperidone Schizophrenia & bipolar Disorder 
Vivitrol 2006 PLGA/naltrexone 
Alcohol dependence & opioid 
dependence 
Somatuline 2007 PLGA/lanreotide Acromegaly 
Ozurdex 2009 PLGA/dexamethasone Macular edema 
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Figure 1-2 Schematic differences between nanoparticles as drug delivery system, adapted from [33]   
The lipid-based carriers, also have significant disadvantages including production cost and 
leakage of encapsulated drug. This has led to the development of alternative carriers such as 
biodegradable polymeric nanoparticles including polymer-drug conjugated nanoparticles. The 
advantages and disadvantages of liposome systems are tabulated in Table 1-3. Biodegradable 
polymeric nanofibres are other nanocarriers and are discussed later in the next section of this 
Chapter.   
Table 1-3 Advantages and disadvantages of liposomes as DDS [34] 
Advantages Disadvantages 
Increased efficacy and therapeutic index of drug Low solubility 
Increased stability via encapsulation Short half-life 
Non-toxic, flexible, biocompatible, completely 
biodegradable, and non-immunogenic for systemic 
and non-systemic administrations 
Sometimes phospholipid undergoes 
oxidation and hydrolysis-like reaction 
Reduce the toxicity of the encapsulated agent  Leakage and fusion of encapsulated drug 
Site avoidance effect Production cost is high 
Flexibility to couple with site-specific ligands to 
achieve active targeting 
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 Biodegradable Drug Nanocarriers  
Biodegradable polymers are often considered as base materials of nanoparticles and nanofibres 
for drug delivery systems. Various natural and synthetic biodegradable polymers have been 
studied and developed for drug delivery. Biodegradable polymeric nanoparticles have been 
used to deliver various bioactive agents, such as small drugs [35, 36], peptides and proteins 
[37], and plasmid DNA [38]. Poly (lactic acid) (PLA), poly(glycol acid) (PGA), poly (lactide-
co-glycolide) (PLGA), poly (-ε-caprolactone) (PCL) are the most widely used biodegradable 
polymers for DDS development because of their biodegradability, biocompatibility and ease 
of processing [39, 40]. It has been demonstrated that the drug release profile is related and 
therefore can be controlled by the polymer degradation rate. For instance, the drug release 
profile of PLGA encapsulated drug could be controlled by varying the molecular weight of 
PLGA [41].  
Biodegradable block copolymers have also captured the imagination of researchers since the 
early days of drug delivery because of their chemical flexibility [4]. Depending on the choice 
of building blocks, they can be assembled in different nanostructured formats such as 
nanoparticles and nanofibres. A triblock copolymer,  poly(propylene oxide)- poly(ethylene 
oxide)- poly(propylene oxide) (PEO-PPO-PEO) as polymeric micelles has been developed by 
Kabanov et al. to deliver doxorubicin [42]. Yang et al. has synthesized core–shell nanoparticles 
from a biodegradable amphiphilic copolymer, comprising of poly(N-methyldietheneamine 
sebacate) (PMDS) as the cationic block for Ribonucleic acid (RNA) encapsulation, and a 
cholesterol pendant group to increase the hydrophobicity of the core for efficient drug loading 
[43]. Another biodegradable triblock copolymer nanoparticle of  poly(ethylene glycol)-b-
poly(ε-caprolactone)-b-poly(2-aminoethyl ethylene phosphate) (PEG-b-PCL-b-PPEEA) was 
13 
 
developed by Wang et al to deliver paclitaxel [44]. More such block (or triblock) copolymers 
delivery systems have been investigated by various groups [45-48].  
Another DDS approach involves the conjugation to a polymeric carrier to a drug via a cleavable 
bond. Various polymer–drug conjugates have been exclusively studied for the delivery of anti-
cancer drugs [49]. Some of reported anti-cancer drug-polymer conjugates are including 
paclitaxel [50], doxorubicin [51] and camptothecin [52]. Drug-polymeric conjugated carriers 
improve solubility of hydrophobic drugs and extend drug circulation in vivo although they still 
show unexpected release behaviour and side effects in clinical testing [53, 54]. Drugs were 
conjugated to polymers via a hydrolysable ester linker and controlled release was observed 
under defined conditions. The polymer-conjugate displays good aqueous solubility and the 
released drug shows similar pharmaceutical effect as the free drug. The major drawback of 
these polymeric nanoparticle based systems is their relative instability in blood upon systematic 
administration which leads to rapid dissociation and subsequently the burst release behaviour 
[55].  
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1.4 Biodegradable Polymers  
Polymeric materials are rapidly growing for use as biomaterials due to their flexibility [23]. 
Both synthetic and natural polymers have been extensively investigated as biodegradable 
polymeric biomaterials [30, 56]. Biodegradable polymers are classified into hydrolytically 
degrading and enzymatically degrading polymers. The majority of natural biopolymers are 
degraded by enzymatic attack. Hydrolytically degradable polymers are polymers that have 
hydrolytically labile chemical bonds in their back bone. The functional groups susceptible to 
hydrolysis include esters, anhydrides, carbonates, amides, urethanes, ureas, etc [57]. The 
majority of biodegradable polymers are bulk eroding where degradation takes place through 
the whole of the polymer samples over time (Figure 1-3). The erosion of the polymer starts 
with the intrusion of water into the polymer bulk so the whole polymer matrix is affected by 
erosion.   
 
Figure 1-3 Schematic illustration of the changes in a polymer matrix undergoing bulk erosion 
Polyglycolic acid (PGA), polylactic acid (PLA), and poly-ε-(caprolactone) (PCL); 
polyurethane (PU), polyvinyl alcohol (PVA), chitosan and collagen are the polymers most 
Time 
Bulk 
Degree 
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widely used in clinical applications including tissue engineering, DDS etc [58, 59]. Table 1-4 
shows the most common biodegradable polymers and their degradation properties [60, 61]. 
Table 1-4 Degradation time of common biodegradable polymers 
Polymer 
Degradation time 
(months) 
Poly glycolide (PGA) 6 to 12 
Poly-L-lactic (LPLA)  >24 
Poly-D-lactic (DPLA) 12 to 16 
Poly-ε-caprolactone (PCL) >24 
Poly dioxanone (PDO) 6 to 12 
85/15 PLA-co-PGA  5 to 6 
75/25 PLA-co-PGA 4 to 5 
65/35 PLA-co-PGA 3 to 4 
50/50 PLA-co-PGA 1 to 2 
 Poly-ε-caprolactone (PCL) 
PCL is semicrystalline polyester which undergoes hydrolytic degradation due to the presence 
of cleavable aliphatic ester linkages (Figure 1-4). PCL is soluble in a wide range of organic 
solvents and has the ability to form miscible blends with variety of biodegradable polymers for 
used in clinical applications such as PLA, PEO and chitosan [62-64]polymers, with a low 
melting point (55–60°C) and glass transition temperature (-60°C). PCL is degraded by 
hydrolysis of its ester linkages in physiological conditions [56, 65].  
 
Figure 1-4 Chemical structure of PCL 
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It has a very slow rate of degradation (>24 months) compared to the other aliphatic polyesters 
such as PLA, PGA, and PLGA. In vivo degradation of PCL was observed for 3 years in rats by 
Sun et al  [66]. It was observed that the shape of PCL products with molecular weight (MW) 
of 66000 remained undamaged for 24 months after implantation. They then broke into low Mw 
pieces at the end of 30 months. A linear relationship was observed between log MW and time 
and as a result MW of PCL deceases with time (Figure 1-5).  
 
Figure 1-5 Decrease in Mw of PCL capsules with time after implantated in rats [66] 
PCL has received a great deal of attention for use in biomedical applications due to its 
remarkable properties especially in drug delivery systems [67], scaffolds for tissue engineering 
[58], and bone tissue engineering [68]. In the case of drug delivery systems, various studies of 
drugs incorporated in different PCL based formulations have been reported [69]. For example, 
Chawla et al [70] have synthetised Tamoxifen loaded PCL nanoparticles with maximum 
tamoxifen loading efficiency for treatment of positive breast cancer; however due to the fact 
that most of the drug was located on the surface of the nanoparticle instead of being uniformly 
dispersed throughout the nanoparticle volume resulting in burst release behaviour. (Figure 1-
6).  
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Figure 1-6 Tamoxifen loaded PCL nanoparticles (a) , drug release behaviour profile in PBS, pH 7.4 at 37°C(b) 
 Polyvinyl Alcohol (PVA) 
PVA is the only carbon-carbon backbone polymer that is biodegradable. PVA is known to be 
a biodegradable synthetic polymer that can be degraded by single microorganisms and 
symbiotic mixed cultures. It has been reported that the polymer is oxidized by enzymatic 
systems with formation of carbonyl groups along the polymer chain [71]. PVA is a linear 
synthetic polymer produced via partial or full hydrolysis of polyvinyl acetate to remove the 
acetate groups (Figure 1-7).  
 
Figure 1-7 Chemical structure of PVA 
The amount of hydroxylation determines the physical characteristics, chemical properties, and 
mechanical properties of the PVA [72]. The resulting PVA polymer is highly soluble in water 
but insoluble in most organic solvents. The higher the degree of hydroxylation of the PVA, the 
lower the solubility in water and the more difficult it is to crystallize [73]. FDA has approved 
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PVA to be in close contact with food products; in fact, PVA films exhibit excellent barrier 
properties for food packaging systems. PVA is used as a biomaterial due to its biocompatible, 
nontoxic, non-carcinogenic, swelling properties, and bioadhesive characteristics [72, 74] 
 Chitosan (CS) 
Natural polymers derived from biological systems including protein and polysaccharides are 
biocompatible and biodegradable polymers.  They possess low toxicity and offer potentially 
favourable pharmacokinetics in the circulatory system [75, 76]. For example, Lee et al. 
summarized the characteristics of various polysaccharides such as alginate, cellulose, chitin, 
chitosan, hyaluronic acid, and starch that can be used for biomedical applications including 
tissue engineering, wound dressings, drug delivery, and enzyme immobilization [77]. Chitosan 
is FDA approved and has extensively been investigated for biomedical applications such as 
wound and burn dressing material due to its easy applicability, air permeability, water 
absorption ability and non-toxicity, etc [56]. The N-deacetylated derivative of chitin is 
chitosan. Typically, commercial chitosan is approximately 85% deacetylated, which leads to a 
–NH2 functionality of the D-glucosamine residues with some randomly distributed N-acetyl 
glucosamine groups (Figure 1-8) [78, 79]. It is a semicrystalline linear polymer of linked d-
glucosamine and is completely soluble in aqueous acidic solutions [80]. It undergoes 
biodegradation in vivo enzymatically to nontoxic products such as glucosamine and 
oligosaccharides. The rate of degradation of chitosan depends inversely on the degree of 
acetylation and crystallinity of the polymer [80]. Cross-linked chitosan products form attractive 
materials for drug delivery applications where the rate of drug release can be controlled by 
varying the cross-linking density [81, 82]. Chitosan has also shown good anticancer activity, 
mainly due to its polycationic nature.  
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Figure 1-8 Chemical structure of chitin and chitosan 
Many studies have been reported on chitosan used for drug delivery systems. The primary 
amine functional group in chitosan structure makes it a natural choice to conjugate with other 
drugs [83]. Chitosan–thioglycolic acid conjugated hydrogels for in situ gelling was synthetised 
via amide bond formation between the primary amino group of chitosan and the carboxylic 
acid group of thioglycolic acid by Sakloetsakun et al.[28]. Chitosan–thiobutylamidine and 
chitosan–thioethylamidine conjugates were also reported to be used as hydrogel to treat 
wounds [29].   
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1.5 Nanoparticles 
Biodegradable and biocompatible nanoparticles have attracted considerable attention as a 
potential new mode for drug delivery. Their significant advantages over other drug delivery 
systems include high surface area to mass ratio and ease of surface modification which is used 
to bind, adsorb or carry other compounds [84]. They are employed as a strategy to enhance 
solubility of hydrophobic therapeutics, protect the drug from early degradation, enhance 
absorption of the drugs into a targeted tissue, prolong circulation time, prevent undesirable side 
effects, to improve intracellular penetration and control the drug release profile [85]. The term 
nanoparticle is used for both nanospheres and nanocapsules. Nanospheres have a matrix type 
structure which drugs may be absorbed at the particle surface or encapsulated within the 
particle. Nanocapsules are vesicular systems in which the drug is confined to a cavity consisting 
of an inner core surrounded by a membrane [86]. Nanocarriers used for drug delivery have to 
be biocompatible and nontoxic. It is generally accepted that nanoparticles with a smaller size 
have a greater surface area and as a result have better pharmacokinetic properties for in vivo 
applications [87].  
Lipid-based materials, biodegradable polymers and silicon materials are all examples of 
nanocarriers that have been studied as drug delivery systems. The most commonly and 
extensively used polymeric nanoparticles are poly(lactic acid) (PLA), poly-L-lactide-co-glyco-
lide (PLGA), poly(ethylene glycol) (PEG) and poly(-ε-caprolactone) (PCL), poly(alkyl-
cyanoacrylates) (PAC), chitosan and gelatine [88-93]. In general, at the preclinical stage, these 
nanocarriers were successfully applied to the treatment of various diseases, mainly for cancer 
and for infectious diseases [94]. Some representative examples of therapeutic nanocarriers on 
the market are briefly described Table 1-5.  
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Table 1-5 Representative examples of nanocarrier-based drugs in the market [85] 
Brand name 
Type of 
nanocarrier 
Active 
ingredient/drug 
Indications 
AmBisome® Liposomes Amphotericn B Fungal infections 
Doxil® Liposomes Doxorubicin 
Ovarian cancer, and 
breast cancer 
Caelyx® Liposomes Doxorubicin 
Ovarian cancer, and 
breast cancer 
Depocyt® Liposomes Cytarabine Lymphomatous meningitis 
Daunoxome® Liposomes Daunorubicin Kaposi’s sarcoma 
Adagen® 
Polymer–drug 
conjugates 
Adenosine 
deaminase 
Adenosine deaminase enzyme 
deficiency 
Onscaspar® 
Polymer–drug 
conjugates 
l-asparaginase Acute lymphoblastic leukemia 
Pegasys® 
Polymer–drug 
conjugates 
PEGylated IFN-α-
2a 
Hepatitis C 
Genexol-PM® 
Polymeric 
micelles 
Paclitaxel Cancer chemotherapy 
Abraxane® 
Protein(albumin) 
nanoparticles 
Paclitaxel Metastatic breast cancer 
Amphotec® 
Lipid colloidal 
dispersion 
Amphotericin B Fungal infections 
 
Despite the impressive progress made in the design of drug loaded nanoparticles with improved 
specificity, only a few nanoparticles based medicines have reached the market (Table 1-7). 
Except those mentioned in Table 1-5, currently-available nanoparticle technologies have not 
been able to improve the activity of a great number of drugs. The major disadvantages of 
nanoparticles as DDS [94] include:  
 Poor drug loading, as a result, either the quantity of the drug administered is not 
sufficient to reach a pharmacologically active concentration in the body, or the 
amount of the carrier material required is too great, leading to toxicity or undesirable 
side-effects. 
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 Burst release of the encapsulated drug, generally corresponding to the release of the 
drug which is adsorbed at the surface of the nanocarriers. As a consequence, a large  
portion of the drug will be released before reaching its pharmacological target in the 
body, leading to lower activity and more side-effects 
Mesoporous silica nanoparticles (MSNs) have attracted lots of attention for their potential 
biomedical applications. Due to the customized mesoporous structure and high surface area, 
MSNs as drug delivery systems (DDSs) show significant advantages over traditional drug 
nanocarriers [95]. 
 Mesoporous Silica Nanoparticles (MSN) 
Inorganic nanomaterials have special properties that can be exploited for use as nanocarriers. 
Since the discovery of methods for the synthesis of mesoporous silica materials in 1992 [96], 
a large number of them have been explored for biomedical application [97]. Mesoporous silica 
nanoparticles (MSN) are solid materials comprised of a honeycomb-like porous structure with 
thousands of empty channels (mesopores) that are able to absorb/encapsulate relatively large 
amounts of bioactive molecules. MSN’s have become a good alternative for controlled drug 
release applications due to their unique properties such as a large surface area, easily modified 
pore size and volume, as well as being chemically inert and allowing easier chemical 
functionalization of their surface [95, 98, 99]. MSNs, in order to be effective and universally 
applicable nanocarriers, must simultaneously demonstrate multiple characteristics including 
[100]: dispersibility, ability to load and deliver large concentrations of drugs, biocompatibility 
and low toxicity. 
Importantly, silica has good biocompatibility, is accepted by the US FDA and has been widely 
used in cosmetics and as FDA-approved food additives [101]. The biocompatibility of MSN 
with and without surface functionalization has been tested by different methods in a report by 
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Slowing et al [102]. They showed that the viability and proliferation of various mammalian 
cells were not affected by the internalization of MSN. As a result MSNs are used to enhance 
the biocompatibility of several drug delivery systems, such as magnetic nanoparticles [103]  
biopolymers [22], and micelles [104].  
Another advantage of MSNs is their ability to be further functionalised ie reacting the silanol 
groups present both within the pore interiors and on the outer surface. Chemical moieties can 
also be adsorbed onto MSNs resulting functionalised MSNs. For example, the amine 
functionalized MSNs were prepared by Manzano et al [105]. First the MSNs were synthetised 
and then the MSNs were treated with 3-aminopropyltriethoxysilane (APTES) as follows. 
Template-free MSNs were dehydrated under a nitrogen flow and then refluxed with 5 mmol of 
APTES/g SiO2 in toluene. The final products were filtered, washed with a mixture of diethyl 
ether and dichloromethane (1:1) and finally dried. 
Tsai et al [106] synthesized mesoporous silica nanoparticles (MSN) for a surfactant assisted 
controlled release of the hydrophobic drug, Resveratrol. The MSN were used as drug carrier 
for Resveratrol by taking advantage of the hydrophobic environment created by the phosphate 
monoester surfactant (PMES) micelle inside the nanoparticles pores (Figure 1-9). 
 
Figure 1-9 TEM image of susrfactant assited MSN (left), Schematic illustration of the Resveratrol loading and 
release. Reported by Tsai et al [106] 
PME 
Resveratrol 
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This delivery technique showed an increase of the drug loading efficiency and a steady release 
of resveratrol compared to the MSN without surfactant. The hydrophobic back of the surfactant 
helped to adsorb the drug and the surfactant molecules come out together with drug.  
 
Figure 1-10 Release profiles of resveratrol-loaded (▲) PMES–MSN; (■) MSN [106] 
PMES–MSN exhibited a sustained release during the first 4h before reaching the maximum 
release. On the other hand, non-surfactant assisted MSN showed a burst release in the first 5–
10min where almost 80% of the drug was released (Figure 1-10). This indicates that 
Resveratrol was physically adsorbed on the surface of the MSN material compared to that in 
PMES-MSN where Resveratol interacted with PMES as well. This result, in addition to other 
studies reported, show that MSN materials are able to store and gradually release therapeutic 
agents [102, 107-111].  
Numerous studies have been reported of MSN as nanocarriers of drugs. Series of MSNs with 
different pore sizes were loaded with a poorly water-soluble telmisartan (TEL) [112]. The 
release profiles (Figure 1-11) showed that MSNs could retain the drug for up to 60 min due to 
the weak hydrogen bonds between TEL and silanol groups on the surface of MSNs. It was 
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observed that pore sizes affected the release profiles of TEL. As shown in Figure 1-11 the 
release of TEL was faster where the MSN has the larger pore diameter [113, 114].  
 
Figure 1-11 Release profiles of TEL from TEL-MSNs with pore diameters of MSNs for the sample A, B and C 
were 12.9, 7.8 and 3.6 and nm, respectively) 
In another study, thiol functionalized MSNs were synthetized for controlled release of 
doxorubicin (DOX) [115].  As shown in Figure 1-12, DOX loaded MSNs could retain drug 
from long period of time (over 50 h)  in PBS (pH 7.4) as it just released 13% of the loaded Dox 
after 48 h. Conversely, a faster release of Dox was observed when loaded MSNs were incubated 
in artificial urine (pH 6.1) with 63% of DOX content was released after 48 h. This was because 
of the stronger interaction between DOX and thiol group at pH 7.4  is weaker in an acidic 
environment (pH 6.1).  
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Figure 1-12 Release profiles of DOX from DOX-SH-MSN 37 °C in artificial urine (pH 6.1) and PBS (pH 7.4).  
1.6 Nanofibres 
Nanofibres have attracted much attention for various applications such as filtration [116, 117], 
nanocomposite reinforcing for nanotechnology,[118, 119], for substances recovery [120] and 
medical applications [121-123] The advantages of nanofibres are derived from their high 
specific surfaces area and formation of high porous surface [124]. Medical applications of 
nanofibres are included to fabricate wound dressings [125, 126] tissue engineering scaffolds 
[126, 127] and nanofibrous drug (pharmaceutical agent) delivery systems [27, 122, 128]. 
 Electrospinning Process 
There are different techniques to fabricate nanofibres including: phase separation [129], melt-
blown [5], self-assembly [130], phase template [131], and electrospinning [124, 132]. 
Electrospinning has received much attention lately since it is a simple technique to fabricating 
nanofibres from a large variety of polymers in a relatively easy and simple way.  
The setup for electrospinning consists of three major components: a high-voltage power supply, 
a spinneret (a metallic needle), and a collector (a grounded conductor) as shown in Figure 1-
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13 [133]. The spinning mechanism is rather complicated due to complex electro-fluid 
mechanical forces involved. In the process of electrospinning the polymer solution housed in 
a syringe is fed through the spinneret at a constant and controllable rate. The electrostatic field 
exists in the space of the electrospinning device when a high voltage (in the range of 1–40 kV) 
is applied. The electrostatic field charges the solution drop at the nozzle of a spinneret and the 
induced charges are evenly distributed over the surface (Figure 1-23). Under the action of 
electrostatic interactions, the drop is distorted into a conical object that is called a “Taylor cone” 
[134]. The electrified jet can be attracted by the collectors and it is directed towards the 
collector with the opposite electrical charge. As it travels to the collector the solvent is 
evaporated and the solid polymer nanofibre is deposited as a nonwoven mat on the surface of 
the collector.  
 
Figure 1-13 Schematic view of electrospinning process [135] 
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Several parameters can  influence the electrospinning as well as the morphology of the 
nanofibres such as polymer type, polymer MW, polymer concentration, solvent, viscosity, etc 
[136]. These variables are summarized in Table 1-6.  
Table 1-6 Parameters that can affect the morphology of the electrospun fibers 
Polymer properties Solution properties Other properties 
Molecular weight Viscosity Solution feed rate 
Glass-transition temperature Viscoelasticity Voltage 
Solubility Concentration Vapor pressure of the solvent 
 Surface tension Relative humidity 
 Electrical conductivity  
Increasing the electrospinning voltage results in a decrease in the stability of the initiating jet, 
which has been correlated with an increase in the number of beads formed along the nanofibre 
length [137]. The properties of solutions were found to influence the size and size distribution 
of nanofibres significantly. The higher the concentration of polymer results in higher viscosities 
and surface tensions respectively. The diameter of the electrospun nanofibres was found to 
increase with solution concentration according to a power law relationship (Figure 1-14) [138]. 
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Figure 1-14 Effect of electrospinnig conditions on the morphology of the nanofibres a. PCL 11%, 25Kv, 0.4 
mL, 20cm; b. PCL 14%, 25Kv, 0.4 mL, 20cm; c. PCL 14%, 25Kv, 0.4 mL, 10cm; d. PCL 14%, 30Kv, 0.4 mL 
20cm  
  
a b 
c d 
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 Co-axial Electrospinning  
Many modifications have been done on conventional electrospinning in order to improve the 
functionality of the electrospun nanofibres. Co-axial electrospinning is one method of 
producing core-cell nanofibres, with high potential in various applications [139]. A process 
contains the spinneret by inserting inner capillary inside the outer capillary to make co‐axial 
configuration. Both needles are attached to two different reservoirs containing the shell and 
core solutions. The feeding rates of the solutions are controlled separately. The co‐axial set up 
expectedly requires  careful design in order to fabricate core-shell nanofibres (Figure 1-15) 
[139]. 
 
Figure 1-15 Schematic view of core-shell electrospinning technique 
In a conventional electrospinning (single fluid), increase in solution concentration results in an 
increase in the nanofibre diameter. The same effect has been observed in the case of co‐axial 
electrospinning. It has been reported that the increase in the core solution concentration 
increased both the core and overall (core-shell) nanofibre diameters and subsequently an 
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increase in the core diameter resulted in a decrease in the thickness of the shell diameter (Figure 
1-16) [140].  
 
Figure 1-16 The effect of core solution concentration on shell thickness, (A) Smaller core diameter and larger 
shell thickness; (B) Larger core diameter and smaller shell thickness due to the increased concentration of core 
solution  
The significant issue is the interaction between the core and shell phases which determines the 
electrospinnability of the polymer solutions. Numerous exotic uses of co-axial electrospinning 
have been reported recently. 
Hollow tubes with encapsulated enzymes have been fabricated by co-axial electrospinning, 
have been reported by Dror et al. [141], as bioreactors. The reaction substrates would diffuse 
efficiently into the hollow fibres where the encapsulated enzyme would convert them into 
products, which would diffuse out of the tubes again. The enzymes were mixed in an aqueous 
core solution of poly(ethylene oxide) (PEO) for the core while poly(ε-caprolactone) (PCL) 
forms the shell. Different ration of the core/shell systems produced outer shells with different 
morphologies [104] Figure 1-17a is when only PCL used to form the shell resulting in a rough 
surface due to the rapid evaporation of the solvents, and Figure 1-17b when poly(ethylene 
glycol) (PEG) is added to PCL and the tube walls became increasingly porous due to the PEG 
and PCL intermolecular polar interactions.  
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Figure 1-17 SEM images of PCL hollow tubes (a), and PEG/PCL hollow tubes. Reported by Dror et al. [141] 
Park et al, produced core-shell nanofibres from chitosan (CS) and poly(ε-caprolactone) (PCL) 
with levofloxacin encapsulated in the core section using co-axial electrospinning [142]. They 
showed that the presence of drug in core of the CS–PCL core-shell nanofibres exhibited more 
sustained release of levofloxacin compared to that in PCL conventional single nozzle 
nanofibres. As shown in Figure 1-18 the burst release of levofloxacin reduced from 70% in 
PCL nanofibres to 40% in CS-PCL core-shell nanofibres.   
 
Figure 1-18 The release profile of levofloxacin from core-shell nanofibres (Left), and TEM image of a CS–PCL 
nanofibrous (Right). Reported by Park et al [142] 
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1.7 Drug delivery Application and Release Kinetics of Electrospun 
Nanofibres 
Several biodegradable polymers have been electrospun for drug delivery application; ranging 
from natural polymers like collagen, chitosan and silk fibroin to synthetic polymers such as 
poly(lactic acid) (PLA), poly(ε-caprolactone) (PCL), polyethylene oxide (PEO), and 
copolymers such as poly (l-lactide-co-caprolactone) and poly(lactic-co-glycolic acid) (PLGA) 
[143]. Several drugs have been investigated; including anticancer drugs such as paclitaxel and 
doxorubicin [144, 145], antibiotics such as rifampicin and tetracycline hydrochloride [146, 
147], DNA [148, 149], and RNA [150]. In most cases the drugs were simply mixed with a 
polymer and then electrospun. The drug release profiles varied depending on the polymer used. 
The electrospinning conditions only had a minimal effect on the release profile [27, 151-153]. 
Typically, the release of an encapsulated compound from polymeric nanofibres has been 
attributed to solid state diffusion. Drug release kinetics is affected by many factors such as 
dissolution of the drug, drug diffusion through the polymer matrix, polymer degradation 
(erosion and hydrolysis), polymer–drug interactions, drug/polymer ratio and system geometry 
[154]. The release profile of drug from nanofibres is due to the drug diffusion out of the 
polymeric matrix and drug diffusion because of polymer degradation [155, 156]. In the case of 
polymer degradation, the rate of degradation can be controlled to some extent by altering 
parameters such as polymer blend composition and ratio of amorphous to crystalline segments. 
For example, the hydrophobic nature of PLA and PLGA is major problem in a mainly 
hydrophilic biological environment. Degradation rate and hydrophilicity of PLA nanofibres 
were controlled and altered by adding PLGA (LA/GA= 50/50) random copolymer and PLA-
b-PEG-b-PLA triblock copolymer [157]. Table 1-7 shows some electrospun drug loaded 
nanofibres with different biodegradable polymers (copolymers) and their blends for controlled 
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drug release. Table 1.7 provides examples of polymer-drug mixtures that have been formulated 
and electrospun are reported in the literature. 
Table 1-7 Examples of recent drugs loaded electrospun nanofibres reported in the literature [122] 
Polymer Drugs Ref. 
PLA, PEVA and PLA/PEVA Tetracycline hydrochloride [152] 
PLA/PCL Tetracycline hydrochloride [158] 
PCL siRNA [159] 
PCL-co-EEP 
Human glial cell-derived neurotrophic 
factor (GDNF) 
[160] 
PCL-co-PCLEEP Human â-nerve growth factor (NGF) [161] 
PCLEEP siRNA [150] 
PLGA Fusidic acid and rifampicin [146] 
Poly(ester urethane) (PEUU) and 
PLGA 
Tetracycline hydrochloride [147] 
Ethyl cellulose (EC)/ 
polyvinylpyrrolidone (PVP) 
Ketoprofen (KET) [162] 
PLGA poly(ethylene glycol)-g-
chitosan (PEG-g-CHN) 
Ibuprofen [163] 
PVP/zein Ketoprofen (KET) [164] 
PLGA Mefoxin [165] 
Poly(ethylene oxide) (PEO) Bovine serum albumin (BSA) [166] 
PLA Lysozyme [167] 
Poly(l-lactide-co-caprolactone) Human-nerve growth factor(NGF) [168] 
PEG–PLA Doxorubicin hydrocloride(Dox) [145] 
PEG–PLA Doxorubicin hydrochloride [169] 
PLLA Doxorubicin [170] 
PEG -â-cyclodextrin Hydroxycamptothecin (HCPT) [171] 
PLA–PEG and PLGA DNA [149] 
PLGA/gelatin Fenbufen [172] 
PCL/PVA HRP encapsulated liposomes [173] 
PLGA Paclitaxel [174] 
PLA/PLGA Cisplatin [175] 
PLA Dichloroacetate (DCA) [176] 
PEG–PLLA 
1,3-Bis(2-chloroethyl)-1-nitrosourea 
(BCNU) 
[177] 
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A major drawback of drug loaded nanofibres reported in the literature is the early release 
behaviour of the drug from the nanofibres called burst release. Burst release occurs when a 
large portion of drug content is released from the nanofibres rapidly after incubation in the 
release medium (Figure 1-19) [163, 178, 179]. Although, the burst release of drug may be 
favourable in some cases such as antibacterial wound dressings and inhibition of the tumour 
cell growth by providing sufficient initial dosage of the antibacterial/anticancer drug within a 
short time period, but the sustained release pattern is desired to maintain constant therapeutic 
concentration of drug over an extended period of time [180, 181] . The major disadvantage of 
the initial burst release of drugs  is toxicity due to high drug dose administration, rapid loss in 
drug affinity, and an increase in dosing frequency [182].  
 
Figure 1-19 Common release profiles: burst release (…..) and desired controlled release (-----) [180] 
 
The release profile of doxorubicin from PEG-PLA nanofibres shows a burst release pattern 
where around 50% of the drug content was released during first 3 hr of incubation [145].  
In another study [183], the burst release of bovine serum albumin (BSA) from core-shell PCL-
PEG nanofibres was observed with the 50% of BSA content released within 2 days (Figure1-
20). 
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Figure 1-20 Release profile of BSA from co-axial PCL-PEG nanofibres   
Figure 1-21 shows the release profile of ketoprofen from tri-layered meshes 
polyvinylpyrrolidone/ethyl cellulose (PVP/EC/PVP) with different electrospinng time of PVP. 
Burst release behaviour was observed in both cases; with around 60% of drug content were 
released in the first 10 h. Increasing the PVP contents (by spinning time of PVP meshes) 
increased the drug release rate. This could be related to hydrophilic properties of PVP, 
increasing hydrophilicity increasing the drug release rate.  
 
Figure 1-21 Release profiles of ketoprofen from EC/PVP nanofibres (Different spinning time of PVP) adapted 
from [162] 
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Fenbufen (FBF) release behaviour from PLGA/gelatin (9/1) nanofibres showed (Figure 1-22) 
the burst release behaviour of FBF with around 70% release of FBF content in the first 5 h.  
 
Figure 1-22 Release profile of FBF from PLGA/gelatin nanofibres adapted from [172] 
Liu et al [170] fabricated doxorubicin (DOX) loaded poly(L-lactide) (PLLA) nanofibres with 
different DOX concentration to study the efficacy of DOX-loaded PLLA electrospun 
nanofibres as a local chemotherapy system. As shown in Figure 1-23, burst release of DOX 
was observed for both DOX concentrations (3 and 6% units) with around 50% of DOX content 
released in the first 10 h. This burst release was related to rapid diffusion of DOX, in the release 
medium, due to its high hydrophilicity, large specific surface area of the nanofibre complex, 
and to the hydrolysis and degradation of PLLA in vivo.  
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Figure 1-23 Release profiles of DOX from PLLA with 3% and 6% DOX, adapted from [170] 
 The burst release provided high local DOX concentrations in the tumor site achieving effective 
inhibition of tumor within a short time period. However due to rapid release of DOX content, 
DOX-PLLA nanofibres cannot provide sustained drug supply to prevent the recurrence of the 
tumour.   
Ibuprofen (IBU) was loaded into MSN and then uniformly encapsulated in PLLA electrospun 
nanofibres [184]. The release profile of IBA showed that electrospun PLLA/IBU-MSN 
composite nanofibres significantly reduced the initial burst release to 6% of  IBU released in 
the first 12 h compared to 46% released from electrospun PLLA–IBU nanofibres at the same 
time (Figure 1-24) [184]. The release of IBU from PLLA nanofibres is affected by drug 
diffusion from the nanofibres into the release medium. In contrast, the entrapment of drug into 
nanoporous structure of MMSs which were further encapsulated in the PLLA nanofibres 
provided two stages of drug diffusion. First drug diffusion is from the MSN into the PLLA 
nanofibres and then drug diffusion from the PLLA nanofibres into the release medium. Such a 
sequential diffusion of drug resulted in a lower initial burst and longer  term of sustained release 
of drug from composite nanofibres [185].  
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Figure 1-24 Release profiles of IBU from electrospun PLLA/IBU and PLLA/IBU-MSN, adopted from [184]  
Similar studies of drug-nanoparticles/nanofibres composite have been reported. Doxorubicin 
(DOX) loaded MSNs were fabricated and incorporated into poly(L-lactic acid) (PLLA) 
nanofibres. The release profiles of DOX indicated that uniform DOX loaded s nanofibres have 
an initial burst release with over 45% of DOX was released after 3 days followed by a sustained 
release over 20 days. In contrast, the presence of DOX loaded MSN incorporated with 
nanofibres, PLLA/DOX-MSNs composite nanofibres,  reduced the burst release to 25% of 
DOX content was release after the same time [181]. The initial burst release is due to the 
distribution of DOX molecules close to the surface of nanofibres during the electrospinning 
process while the MSN/-nanofibres composite mats could be tailored to provide a slow release 
followed by a sustained release of the drug.  
In another study, incorporating coumarin 6 (C6) loaded PLGA nanoparticles into PVA 
nanofibres reduced the burst release of C6 from C6-PLGA nanoparticles. The release profile 
showed burst release with the whole encapsulated C6 content was released from nanoparticles 
within 2 h due to the short diffusion of C6 in the matrix (Figure 1-25). In contrast, incorporating 
C6-PLGA nanoparticles into PVA nanofibres significantly decreased the burst release to 
approximately 70% after 2 h.  
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Figure 1-25 Release profiles of C6 from PLGA nanoparticels (Left), and PVA/C6-PLGA nanofibres  
These results indicated that the inclusion of C6-PLGA nanoparticles within the PVA nanofibres 
implied two diffusion steps. First through the nanoparticles and then followed by a second 
diffusion step through the PVA matrix in to the release medium [186]. 
1.8 A Model Drug, Levofloxacin 
In order to investigate the release profiles of composite nanofibres, easy detection of the model 
drug (agent) is necessary. LVF was used as a model drug in this work because of its 
chromophore for easy detection, max 290 nm. It also has functional groups such as carboxylic 
acid group that can be used for further chemical modification (i.e. conjugation).  
LVF, a fluoroquinolone antibacterial agent, is active against most aerobic gram-positive and 
gram negative organisms. LVF penetrates rapidly and efficiently throughout the body, 
achieving concentrations in tissues or body fluids which are generally higher than those 
observed in plasma. Within 24 h of an administration, about 80% of the drug is excreted 
unchanged in the urine. That means the plasma elimination half-life of LVF is 4 to 7 h. It has 
demonstrated antibacterial efficacy against a variety of infections, including respiratory tract, 
genitourinary, obstetric, and skin tissue in clinical trials. It has a broad range of in vitro activity 
against most aerobic Gram-negative bacteria.  Inhibition of bacterial multiplication by LVF 
Time (h)      Time (h) 
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was not influenced by growth medium types. Acidic pH may reduce the in vitro antibacterial 
activity of LVF. LVF usually has additive or indifferent effects when combined with other 
antibacterial agents in vitro, but may occasionally show synergy or antagonism [187]. 
 
Figure 1-26 Chemical structure of Levofloxacin 
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1.9 Research concepts and hypotheses 
This thesis investigates the scope of fabricating drug loaded electrospun nanofibres. The main 
objective is to fabricate drug-nanofibres composite mats through physical and chemical 
approaches and characterise and compare the drug release profiles of composite nanofibres 
with uniform drug loaded nanofibres. The major challenge is to overcome the the problem of 
burst release profile of drug from conventional and uniform nanofibres. The scope of this 
research is to derive a suitable means of reducing the burst release of drug. The possibilities 
are:  
1.  Introduction of nanoparticles during the electrospinning process to fabricate core-
shell nanofibres. The hypothesis is to control the release of drug by combining two 
drug delivery systems.  
2. Use of conjugation  to chemically bind the drug to the nanocarriers, incorporating 
them into biodegradable composite nanofibres by electrospinning. The hypothesis is 
to reduce the burst release by hydrolysis of the cleavable bind between drug and 
nanocarriers.  
 Aims and objectives 
The main objective of this research project is to reduce the burst release of drug from 
electrospun nanofibres followed by sustained release. The detailed objectives of the current 
study are: 
1. To fabricate LVF-loaded MSN complexes as nanocarriers of LVF. 
2. To fabricate the core-shell PCL/LVF-MSN composite nanofibres. 
3. To investigate the loading efficiency of LVF-MSN complexes and core-shell structure 
of composite nanofibres. 
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4. To investigate the effect of MSN and core-shell structure of nanofibres in the release 
profiles of LVF. 
5. To determine the antimicrobial activity of the core-shell composite nanofibres 
6. To synthesize the conjugated LVF/functionalized MSN. 
7. To investigate the conjugation efficiency of LVF-MSN and their release profiles in 
different pH buffer solutions 
8. To fabricate PCL/conjugated LVF-MSN composite nanofibres via electrospinning.  
9. To investigate the effect of LVF-MSN conjugation on the release profiles of different 
composite nanofibres. 
10. To synthesize LVF-chitosan conjugation and to investigate the conjugation. 
11. To fabricate composite PVA/LVF-chitosan composite nanofibres via electrospinning.  
12. To investigate the effect of presence of conjugated drug-polymer on the release 
profile of composite PVA nanofibres.  
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2 Chapter 2 
 
 
 
 
 
MATERIALS, METHODS AND 
CHARACTERIZATION TECHNIQUES 
This chapter presents the materials that have been utilized in the fabrication of the electrospun 
composite materials used in this thesis as well as the methods used to characterise them. The 
characterisation methods include TGA, DSC, FTIR, NMR, EDX, BET & BJK analysis, and 
electron microscopy (SEM and TEM). The chapter also presents the method for measuring the 
in vitro drug release profile of electrospun nanofibres and drug-nanoparticles complexes, and 
the quantitative antimicrobial assay (AATCC Test Method 100–1999) used to measure the 
efficacy of the electrospun composite mats.   
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2.1 Materials  
The following is the list of the materials used in this research work.   
Polymers 
 Poly(ɛ-caprolactone) (PCL) with a molecular weight (MW) of 80,000g/mol, (Sigma-
Aldrich, Australia) 
 Polyvinyl alcohol (PVA) with an average MW of 77,000-79,000g/mol, , 98% 
hydrolyzed, (Sigma-Aldrich, Australia) 
 Chitosan (low molecular weight),75-85% deacetylated, (Sigma-Aldrich, Australia)  
Nanoparticles  
 Mesoporous silica nanoparticles (MSN), with linear formula SiO2 , 200nm particle 
size, pore size 4nm, melting point >1600 ºC, (Sigma-Aldrich, Australia) 
 Propylthiol functionalized mesoporous silica nanoparticles (MSN-SH), 200nm 
particle size, pore size 4nm,  melting point 1600-1725ºC, (Sigma-Aldrich, Australia) 
Drug 
 Levofloxacin (LVF) (≥98.0%), with molecular weight (MW) of 361.37g/mol , (Sigma 
Aldrich, Germany) 
Chemicals 
 N,N-dimethylformamide (DMF) anhydrous, 99.8% , (Sigma-Aldrich, Australia) 
 Dichloromethane (DCM) anhydrous, ≥99.8% , (Sigma-Aldrich, Australia) 
 Tetrahydrofuran (THF) anhydrous, ≥99.9% , (Sigma-Aldrich, Australia) 
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 Acetic acid, ≥99.7% , (Sigma-Aldrich, Australia) 
 Sodium hydroxide (NaOH), (Merck, Germany) 
 Potasium chloride (KCl), (Sigma-Aldrich, Australia) 
 Disodium hydrogen phosphate (Na2HPO4), (Sigma-Aldrich, Australia) 
 Potassium dihydrogen phosphate (KH2PO4) , (Sigma-Aldrich, Australia)  
 Tryptone (Peptone from casein), (Sigma-Aldrich, Australia) 
 Yeast extract, (Sigma-Aldrich, Australia) 
 Agar, (Sigma-Aldrich, Australia) 
 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), (Pierce) 
 Dimethyl sulfoxide (DMSO), (Fisher Chemical) 
 2-(N-morpholino)ethanesulfonic acid (MES), (Fluka) 
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2.2 Characterization Techniques 
 The electrospun membranes and drug-nanoparticles complexes were characterised using the 
following techniques, Thermogravimetric Analysis (TGA), Differential Scanning Calorimetry 
(DSC), Infra-Red Spectroscopy (FTIR), BET & BJK surface area and pore sizes analysis, 
Nuclear Magnetic Resonance (NMR), Scanning Electron Microscopy (SEM), and 
Transmission Electron Microscopy (TEM).  
 Thermogravimetric Analysis (TGA) 
Thermogravimetric analysis (TGA) measures changes in physical and chemical properties by 
increasing temperature as a function of time. Physical properties measured includes phase 
transitions, including vaporization, sublimation, absorption, adsorption, and desorption. 
Chemical properties measured include chemisorption, decomposition and solid-gas reactions. 
TGA can also determine either mass loss or gain due to decomposition or oxidation [1]. 
Furthermore, TGA can evaluate the thermal stability of a material. In a specific temperature 
range; if a material is thermally stable, no mass change will be observed. The TGA instrument 
continuously weighs a sample as it is heated to temperatures of up to 2000°C. Usually as the 
temperature increases, decomposition occurs and the decomposition components can be 
evaluated using mass loss (reported as %loss of mass) or even techniques such as mass 
spectrometer or infra-red spectrophotometry. Results are plotted with temperature on the X-
axis and mass loss on the Y-axis (Figure 2-1).  
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Figure 2-1 TGA analysis of levofloxacin 
TGA has a wide variety of applications, including analysis of ceramics and thermally stable 
polymers. Samples in this dissertation were analysed using a Netzsch STA 449 F1 Jupiter 
Simultaneous TGA/DSC Thermal Analyser system (Figure 2-2).  
 
Figure 2-2 Netzsch STA 449 F1 Jupiter Simultaneous TGA/DSC Thermal Analyser 
62 
 
 Differential Scanning Calorimetry (DSC)  
Differential Scanning Calorimetry (DSC) is another thermal analysis tool in which the amount 
of energy absorbed or released by a material in relation to an inert reference is measured as a 
function of temperature, while both sample and reference are subjected to identical temperature 
programs. DSC basically consists of sample and reference holders, a heat sink and 
thermocouples. Heat flow is delivered from the heat sink to the sample and reference holders 
to increase or decrease temperature (Figure 2-3) [2]. DSC records the required energy to 
maintain the temperature of both the sample and reference. Output from a DSC includes the 
glass transition temperature and melting point as well as information on crystalline structure 
(Figure 2-4). For one major part of this project, which deals with studying the presence of 
crystalline drug in conjugated products, DSC provided a means to determine the changes in 
drug melting point and crystallisation after conjugation and providing an indirect means 
confirming conjugation.  
 
Figure 2-3 Schematic of a DSC 
In order to plot the DSC endotherm or exotherm, heat is transferred to the sample and reference 
pans through a disc made of either constantan or silver. The heat difference between the sample 
and reference is measured by a thermocouple located beneath the pans. The temperature 
difference signal is converted to heat flow by a calibration equation [3]. 
63 
 
 
Figure 2-4 DSC spectrum of Levofloxacin, up to 300 °C in the presence of N2 
 Fourier Transform Infra-Red Spectroscopy (FTIR): 
Any organic or inorganic substance having covalent bonds absorbs various frequencies of 
electromagnetic radiation in the infrared region of the electromagnetic spectrum. This region 
lies at wavelengths longer than those associated with visible light,. Infrared (IR) spectroscopy 
has been widely used to characterise the chemical structure of materials. This technique is 
based upon the vibrations of atoms of a molecule. An infrared spectrum is obtained by exposing 
the infrared through a sample and determining what fraction of the incident radiation is 
absorbed at a particular energy. The frequency at which any peak in the absorption spectrum 
appears corresponds to the frequency of a part of sample molecules [4]. These frequencies are 
correlated to specific functional groups. 
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Figure 2-5 Schematic diagram of typical FTIR spectrophotometer 
Infrared spectroscopy is usually carried out using a Fourier transform infrared (FTIR) 
spectrometer. A schematic diagram of an FT-IR (Figure 2-5) shows the basic components. The 
FT-IR uses an interferometer to process the energy sent to the sample. In the interferometer, 
the source energy passes through a beam splitter, a mirror placed at a 45° angle to the incoming 
radiation, which allows the incoming radiation to pass through but separates it into two 
perpendicular beams. When the two beams meet at the beam splitter, they recombine. The 
combined beam containing these interference patterns is called the interferogram. This 
interferogram contains all of the radiative energy coming from the source and has a wide range 
of wavelengths. Then, it is passed to the sample before reaching a detector. Data received by a 
computer receiver is converted to digital data and then transferred to the computer for Fourier 
transformation to take place. [5]. An example result obtained from the FTIR spectroscopy is 
shown in Figure 2-6, the spectrum of levofloxacin taken between 600-4000 cm-1 in 
transmission mode.  
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Figure 2-6  LVF spectrum taken between 600-4000 cm-1 wavelength 
 
Figure 2-7 Thermo Nicolet 6700 FTIR Spectrometer 
FTIR was also used to determine any changes in the chemical structure of nanocarriers after 
loading and conjugation. Samples were carried out using Fourier transform infrared (FTIR) 
(Figure 2-7) spectrometer ranging between 600 and 4000cm-1, with a total of 16 scans. 
  
0
0.5
1
1.5
2
2.5
3
3.5
5001000150020002500300035004000
Wavelength (cm-1)
66 
 
 BET/BJH Surface Area and Pore Size Distribution Analysis  
The specific surface area of a fine particle is determined by physical adsorption of a gas onto 
the surface of the solid and by calculating the amount of adsorbed gas corresponding to a 
monomolecular layer on the surface. The BET theory describes the changes in pressure during 
multi-layer adsorption of inert molecules onto a surface [6, 7]. This is usually carried out at 
liquid nitrogen. The amount of gas adsorbed can be measured by a volumetric or continuous 
flow procedure. The data is treated using the BET adsorption isotherm equation 
characterisation first proposed by Brunauer, Emmett and Teller (BET) [8]:  
 
Equation 2-1 
where W is the amount of absorbed gas in moles, Wm is the amount of gas to form a monolayer 
in moles, PV and PO are the gas vapour pressure (Pa) and the equilibrium vapour pressure (Pa), 
respectively. C is a constant rate related to the absorption energy of the gas molecule to a solid 
substrate.  
The Barrett-Joyner-Halenda (BJH) method is used for calculating pore size distributions and 
volumes. This is a method based on a model of the adsorbent as a collection of pores. The 
method accounts for capillary condensation in the pores using the classical Kelvin equation. In 
each pore the total excess adsorption is given by a surface layer thickness t(P) plus a pore-
filling term [9].  
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Equation 2-2 
Where rc = r – t(P) and r is the radius of the pore. VL is the molar volume of the liquid, γ is the 
surface tension, and P° is the vapour pressure. This analysis requires independent 
determination of γ, VL, P° , and the reference isotherm t(P).   
Nitrogen adsorption-desorption isotherms were measured using a Micrometrics Tristar 3000 
BET surface area analyser (Micrometrics, USA), pore volumes and pore sizes of the MSN 
before and after loading the drug were determined from the desorption branches of isotherms  
by the Barrett-Joyner-Halenda (BJH) method. The specific surface area was calculated 
according to the Brunauer-Emmett-Teller (BET) method [10-12].  
 Nuclear Magnetic Resonance (NMR):  
Nuclear magnetic resonance spectroscopy (NMR) provides comprehensive data in relation to 
the structure, chemical environment of molecules, dynamics and reaction state. NMR 
spectroscopy is commonly used to investigate the properties of organic and inorganic materials, 
although it is only a relevant technique for nuclei possessing a spin [13]. NMR gives 
information about the number of magnetically distinct atoms. A hydrogen nucleus (1H) 
behaves as a small magnet in the presence of a magnetic field so for nuclei with spin ½ it will 
align with an external magnetic field or opposed to it. Again, the alignment where it is opposed 
to the field is less stable (at a higher energy).  
The nuclear magnetic resonance phenomenon occurs when nuclei aligned with an applied field 
are induced to absorb energy and change their spin orientation with respect to the applied field. 
68 
 
Figure 2-8 illustrates this process for a hydrogen nucleus. The energy absorption is a quantized 
process, and the energy absorbed must equal the energy difference between the two states 
involved. 
Eabsorbed = (E -1/2state – E+1/2state) = hv 
Equation 2-3-2  
 
Figure 2-8 The NMR absorption process for a proton 
Each proton in a molecule is shielded from the applied magnetic field to an extent that depends 
on the electron density surrounding it. The counter field that shields a nucleus diminishes the 
net applied magnetic field that the nucleus experiences. Each proton in a molecule is in a 
different chemical environment and consequently has a slightly different amount of electronic 
shielding, which results in a slightly different resonance frequency. Measuring the exact precise 
frequencies is very difficult; so the resonance frequency of each proton is measured relative to 
the resonance frequency of the protons of the reference substance. Tetramethylsilane (TMS) is 
the standard reference substance which is used commonly. Therefore, when measuring another 
compound, the resonances of its protons are reported in Hertz are shifted from those of TMS. 
The shift from TMS for a given proton depends on the strength of the applied magnetic field. 
The chemical shift in δ units expresses the amount by which a proton resonance is shifted from 
TMS, in parts per million (ppm), of the spectrometer’s basic operating frequency [13].  
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The chemical structure of a polymer/nanoparticles/ or drug subjected to conjugation process 
may be substantially different from the original (due to cross linking after drug-
nanoparticle/polymer conjugation). NMR was used to study the chemical composition of the 
drug ,nanoparticles and polymers before and after conjugation. 13C NMR spectra were 
collected from the solid state NMR experiments performed on an NMR spectrometer (Bruker 
BioSpin Av500) operating at 125.8 MHz. Samples were packed into a 4 mm ZrO2 rotor and 
spun at 5 kHz in a standard-bore 4 mm broadband MAS probe. Data were processed in Bruker 
BioSpin TopSpin v3.0. 
 Scanning Electron Microscopy (SEM): 
Scanning electron microscopy (SEM) is a form of electron microscopy that produces images 
of a sample by scanning with a focused beam of electrons. The electrons interact with atoms in 
the sample, contain information about the sample's surface topography and composition. SEM 
can achieve resolution better than 1 nm. Specimens can be observed in high vacuum, in low 
vacuum, in wet conditions, and at a wide range of cryogenic or elevated temperatures. The 
schematic diagram of SEM is shown in Figure 2-9 consisting of an electron gun, a series of 
electromagnetic lenses and apertures. An electron beam is emitted from the electron gun and it 
passes through several electromagnetic lenses, including condenser lenses and an objective 
lens. When the electrons hit on the sample surface, they produce inelastic scattering. During 
the inelastic scattering, an incident electron transfers kinetic energy to an electron in a sample. 
With a sufficient kinetic energy, this electron will become a secondary electron. The secondary 
electrons are then collected by a detector and amplified by an amplifier to produce an image 
[14]. 
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Figure 2-9 Schematic diagram of scanning electron microscope [15] 
 Transmission Emitted Microscope (TEM): 
A transmission electron microscope differs from a scanning electron microscope in that the 
electron beam used to create an image is passed through an ultra-thin sample instead of being 
reflected or emitted from the sample surface. Therefore, in contrast to SEM, this technique 
results in a 2D image and can be utilised to provide information about the structures and 
components within a sample.  
TEM consists of electron source, condenser lens, objective lens, projection lens and image 
plane on fluroscent screen, as shown in Figure 2-10. In a TEM, the electron source, generally 
a tungsten filament is heated with a low voltage source. The electron source generates a beam 
of electrons which is then focused on the sample by condenser.  The filament is held at a large 
negative potential and the electrons are accelerated towards the sample with less than 100 nm 
thickness. Similar to SEM, X-rays escape from the material surface and the X-rays detected. 
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After the electron beam passes through the sample, transmitted beams accordingly pass through 
the other lenses and finally an image is produced [2, 16]. 
 
Figure 2-10 Schematic diagram showing the signals used for transmission electron microscopy [17]  
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2.3 Methods 
 In Vitro Drug Release  
Absorption spectroscopy in the UV region is a highly effective tool in the analysis of 
chemical compounds. The main emphasis in the following thesis was to monitor drug release 
rate from nanofibres and nanoparticles. UV/Visible spectrophotometry is widely used to 
determine the amount of released drug. The principle of UV/Visible spectrophotometer is 
shown in Figure 2.11. The wave lengths of ultraviolet and visible lights in the range of 200nm 
- 800nm are utilized by the equipment. The energy of waves corresponds to the difference of 
electron condition energy in atoms, molecules or groups within molecules such as aromatic, 
conjugated chromophores etc. Therefore the spectrum obtained through the detector shows 
intensity of absorbed light as well as the information of sample molecules. By this theory the 
drug release profile of the sample in buffer is determined [2]. 
 
Figure 2-11 Principle of UV-Visible spectrophotometer  
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The following equation applies to the solution used in the laboratory.  Beer’s law provides a 
relationship among absorbance, molar absorptivity (ε), path length (b) and molar concentration 
(c) [18]:    
A = εbc 
 
Figure 2-12 UV/Vis spectrum of LVF, indicating the max at 290nm 
A UV/Vis spectrum of the model drug utilized in this research, LVF, strongly absorbs at 290nm 
(Figure 2-12). The calibration plot of UV absorbency of LVF in the concentration range of 0-
20 mg/ml (max = 290 nm) (5 data points/concentrations) was prepared in buffer solution 
(Figure 2-13). The linear part of the calibration plot is used to determine the concentration of 
the released drug in release buffer based on the UV absorbency. The percentage of the released 
drug was then calculated based on the initial weight of the drug incorporated in the electrospun 
nanofibres and nanoparticles.  
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Figure 2-13 Standard calibration plot of UV absorbency of LVF 
In the following thesis, UV/Vis spectra were obtained on a Cary 300 Bio spectrometer shown 
in Figure 2-14, operating at a resolution of 1 nm over a wavelength range of 200-800 nm. 
 
Figure 2-14 UV-Vis Spectroscopy (VARIAN CARY 300) used in the project 
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 Determination of Total LVF Content of the Samples 
A known weight of the electrospun mats or nanoparticles (e.g. 10mg) was suspended in 10mL 
of alkaline solution of pH 9.0 (sodium hydroxide solution) [19]. The electrospun mats or 
nanoparticles were stirred for 24h at 60°C and the amount LVF released was determined by 
sampling the solution and measuring its absorbance at 290 nm. 
 LVF Release from Electrospun Mats and Nanoparticles 
In vitro dissolution testing is a requirement for drug dosage forms and is used in all phases of 
development for product release and stability testing based on FDA guidance on dissolution 
testing [20]. Dissolution testing is an in vitro method that characterizes how the drug is 
extracted out of a solid dosage form. The analysis is carried out at certain time points by 
removing aliquots of release medium and analysing for drug content by UV-Vis. In this thesis, 
the release of the LVF from the electrospun mats and nanoparticles the films was determined 
by placing a known mass of the composite in known volume (e.g. 10 mL) of phosphate buffer 
saline solution (PBS, 100 mM, pH 7.4 and pH 9.0) and shaken at 150 rpm at 37°C. At each 
time point 1mL of release medium was removed and replenished with an identical fresh release 
buffer. The amount of released LVF at each time point was determined by UV 
spectrophotometer. The UV absorbancy of LVF in buffer solutions was measured at 290 nm 
and converted to the LVF concentration according to the calibration curve. LVF release profiles 
were calculated from the LVF concentration at each time points by following equations:  
Cr= Ca × Vb 
R(% )= (Cr / Td) × 100 
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Where Cr is the released drug in the medium, Ca is drug content in 1mL, Vb is total volume 
of the release medium,  Td is total drug content of the samples, and R is the percentage of total 
drug content released,    
 Antibacterial Assay 
The antimicrobial activity of the core-shell electrospun composite nanofibres in chapter 3 was 
assessed quantitatively against Gram-negative E. coli. The principle of the test is killing the 
bacteria by intimate contact with electrospun mats. 
Antimicrobial efficacy of the electrospun composite mats were carried out as per AATCC Test 
Method 100–1999 using E. coli (ATCC 4352) as the test species. The cells were cultured in 
LB nutrient broth yeast extract consisting of 5g/L, tryptone 10g/L, and NaCl 10g/L, pH 7.2. In 
these assays, 0.03 mL of overnight culture (diluted to 4×108 cells/mL with nutrient broth) was 
applied to four layers of electrospun mats (14.3 mm in diameter). Care was taken to ensure that 
the bacterial solution was fully adsorbed without any excess liquid remaining. The electrospun 
mats were placed in humidified sealed jars (250 mL) and incubated for 4 h at 37°C. The bacteria 
were eluted with 100 mL of sterile water by vigorous shaking. The total number of live E. coli 
cells was counted after serial dilution and plating on nutrient agar plates (Figure 2-5). The 
percentage of bacterial reduction was calculated from the following equation: 
𝑩𝒂𝒄𝒕𝒆𝒓𝒊𝒂𝒍 𝒓𝒆𝒅𝒖𝒄𝒕𝒊𝒐𝒏 (%) = 𝟏𝟎𝟎 − (𝑪 − 𝑨)/𝑪 
where A is the number of colonies from the test electrospun mats after 4 h of incubation and C 
is the number of colonies from PCL electrospun control mats (no drug) at time zero. Figure 2-
5 shows the schematic view of the whole procedure. 
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Figure 2-15 The schematic of Antimicrobial test method – AATCC Quantitative Method 100-1999 
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3 Chapter 3 
 
 
 
 
 
RELEASE AND ANTIMICROBIAL ACTIVITY 
OF LVF FROM COMPOSITE MATS OF PCL 
AND MSN CORE–SHELL NANOFIBRES 
Published in Journal of Materials Science, 50.24 (2015): 7967-7974 
The paper published in the Journal of Materials Science in August 2015 [1] is based on the 
work described in this chapter.  It demonstrates sustained release of LVF by combining two 
drug delivery systems. First, LVF was loaded into mesoporous structure of MSNs (as a 
biocompatible nanocarrier) and then LVF-MSN complexes were confined into the core section 
of core-shell biodegradable PCL nanofibres produced by co-axial electrospinning.  
 
 
81 
 
3.1 Abstract 
Nanofibrous materials have often been reported as carriers for clinical drugs but face the 
limitation of releasing the drugs in a burst fashion on application. The aim of this study is to 
produce composite nanofibrous mats with sustained release, using the broad spectrum 
antibiotic levofloxacin (LVF) as a model. Sustained release was achieved through two 
approaches, i.e. by firstly loading LVF into mesoporous silica nanoparticles (MSN) and then 
incorporating the MSN in the core regions of poly(ε-caprolactone) (PCL) nanofibres via core-
shell electrospinning. Uniform PCL/LVF nanofibrous mats were also produced as controls. 
Loading of LVF into the MSN nanopores was confirmed by FTIR, TGA, BJH and BET 
measurements. After electrospinning, electron microscopy revealed that the MSN was  
confined in the core regions of the nanofibres. Drug release profiles showed that burst release 
was decreased from 59 % in the uniform PCL/LVF electrospun mats to 39 % in the core–shell 
PCL/LVF–MSN mats after 1 day in phosphate buffer at 37 °C. Gradual release in the latter 
was observed over the next 13 days. Antimicrobial assays showed that the composite 
electrospun mats were highly effective in killing Escherichia coli even after the mats had been 
incubated in a phosphate buffer for 14 days while the uniform PCL/LVF mats lost the ability 
after only 7 days. The results show that adsorption of the drug onto MSN and confining  it in 
the core of nanofibres is an effective way of minimizing burst release and achieving sustained 
release of the drug.  
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3.2 Introduction 
Sustained release of drugs has gained much attention in recent decades [2, 3]. The rationale of 
developing a sustained release system includes extending the duration of action of the drug, 
reducing the frequency of dosing and improving therapeutic efficacy by providing a constant 
drug level (as opposed to the application of several high doses) therefore overcoming adverse 
side effects [4]. Drug delivery methods include the adsorption or  incorporation of the drug into 
particles or polymer systems as well as grafting the drug to a polymer backbone [5]. A number 
of different carriers have been explored to control drug release, such as biocompatible micro- 
and nanoparticles, nanofibres, erodible polymer gels, liposomes and polymer micelles [6].   
Electrospinning is a convenient method for fabricating nanofibres which have been used in a 
wide range of applications such as catalysis, filtration, nanocomposites and medical textiles [7-
9]. More recently, electrospun nanofibres are being considered as a drug delivery carrier where 
the drug is blended with the polymer solution prior to electrospinning. In this approach ideally 
the drug is evenly distributed throughout the fibre volume, in order to provide continuous even 
release. In reality there is fast burst release of drugs. The burst release could be caused by 
various reasons such as the presence of the drug on the surface of nanofibres rather than even 
distribution throughout the fibre volume, the degradation rate of the polymer used and the 
larger surface area of the nanofibres due to very small diameter size [10-15]. One approach 
used to prolong drug release is to fabricate core-shell nanofibres via core-shell electrospinning 
with the drug loaded into the core structure [14, 16-18]. This prolonged release profile is 
probably due to the drug molecules being trapped in  the core section of the fibres by the shell 
polymer [19, 20]. The shell must degrade first sufficiently before any drug contained in the 
core is released. For example, Wang et al. [20] studied the release of dimethyloxalylglycine 
from PLLA/PHB nanofibres and found that 25% of the drug was released over a 60 h period 
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in a core-shell situation compared to 80% of the drug released in single component nanofibre 
structure, and attributed the reduction to  the presence of the shell polymer [21-24]. In another 
study core-shell PVP/zein nanofibres with ketoprofen in core section were fabricated for 
providing biphasic drug release profiles. It was observed that the core-shell nanofibres showed 
a first burst release of 42.3% of the contained ketoprofen but then followed by a sustained 
release over a 10h period of the remaining drug [25].   
Another method to achieve sustained release is to adsorb the drug onto/into nanostructure 
carriers such as polymeric nanoparticles and micelles, liposomes, gold nanoparticles and silica 
nanoparticles [7, 26-28]. Mesoporous silica nanoparticles (MSN) have been used as a 
nanocarrier of drugs due to their unique properties such as high specific surface area, high pore 
volumes and the presence of reactive groups for further functionalisation, i.e. covalent 
conjugation to a drug  [29-33]. A recent report by Zhang et al, shows that a poorly water-
soluble drug, telmisartan, was loaded into MSN at a very high drug loading of about 60% in 
weight [34] and the release profile was improved and controlled by decreasing the pore sizes. 
The burst release reduced from 96% from MSN with 12.9 nm pore diameter to 65.7% in MSN 
with 3.6nm pore diameter after 15min. This is due to the restricted diffusion of release medium 
into the small pores and relatively diffusion of telmisartan out of the pores which leads to 
delayed release.  
Another advantage is that MSNs improve the solubility of water insoluble drugs, therefore 
providing an alternative to DDS of hydrophobic or poorly water soluble drugs. Furthermore, 
MSN shows good biocompatibility with no cytotoxicity to cells in vitro, and silica-based 
implants show no toxicity to liver, kidney or lymph nodes in animals. [35-37].  
The aim of this study is to design a sustained drug delivery system based on the advantages of 
MSN and core-shell nanofibres. Levofloxacin (LVF) was adsorbed onto MSN and then 
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fabricated into nanofibre/MSN composites by core-shell electrospinning in order to reduce 
burst release behavior and obtain sustained release of LVF. The release profiles of core-shell 
electrospun composite mats were measured and compared with the control electrospun 
nanofibres and thin films. The polymer in this case was poly(ɛ-caprolactone). PCL was chosen 
due to its slow degradation rate (up to 24 months to complete degradation) [38, 39]. Finally, 
antimicrobial activity of the core-shell electrospun mats was assayed using E. coli [40].  
3.3 Materials and Methods 
 Materials 
Poly(ɛ-caprolactone) (PCL, MW 80000g/mol), MSN (200 nm particle size and 4 nm pore size), 
LVF (98.0%), dichloromethane (DCM) and N,N-dimethylformamide (DMF) were all 
purchased from Sigma-Aldrich. All other chemicals were of reagent grade and used without 
further purification.  
 Methods 
 Preparation of Drug-loaded MSN and Drug-loaded MSN/Electrospun 
Mats 
LVF (75 mg) was fully dissolved in 30 mL deionised water, to which 150 mg of MSN was 
added and the solution was sonicated for 15 min and then stirred for a further 18 h. The MSN 
was collected after centrifuging (15 min at 25,000 g), dispersed in deionized water and 
sonicated for 15 min. This step was repeated twice to remove unbound LVF. The MSN/LVF 
were finally collected after centrifugation and dried at room temperature for 48 h.  
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The basic experimental setup for core-shell electrospinning process is shown in Figure 3-1. 
The setup contained an inner spinneret needle (25G, 0.52 mm outer diameter) placed inside in 
an outer spinneret needle (19G, 1.07 mm outer and 0.69 mm inner diameter) (Figure 3-1), 
syringe pumps (model NE-1000 New Era Pump Systems, Inc., Farmingdale, NY, USA), a high 
voltage supply (Spellman high voltage DC power supply, USA) and two syringes (3 mL for 
the core layer and 5 mL for the shell layer).  The inner and outer spinneret needles produced 
the core and shell components in the resultant nanofibres, respectively. The electrospinning 
distance was varied between 0 and 300 mm (optimised distance of 150 mm) and applied voltage 
was varied between 0 and 40 (optimised value of 20 kV). Electrospun mats were collected for 
10 h on a drum collector (100mm diameter). 
The electrospun mats were prepared containing 1 wt% of LVF and 3 wt% of LVF-MSN (with 
respect to PCL). For core polymer solutions, 20 mg LVF and 60 mg LVF-MSN were added to 
two separate bottles containing 20 g of 10 wt% PCL in a 1:1 (by weight) mixture of DCM:DMF 
and stirred continuously until a homogeneous solution was obtained. A solution of 14 wt% 
PCL was also prepared separately to be used as the shell polymer solution. The control 
electrospun mat and drug/polymer film were made from 1% of LVF (with respect to PCL) 
added to a 14 wt% PCL solution and stirred until a clear solution was obtained.  
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Figure 3-1  Schematic diagram of preparation of LVF-MSN and core-shell PCL/LVF-MSN nanofibres 
Electrospun mats were collected over 4 h period, with core layer pump rates of 0.4 mLh-1 and 
shell layer pump rate of 0.7 mLh-1. For a conventional electrospun nanofibrous mat a single 
pump was used at 0.7 mLh-1. The drum collector was driven by a 12 V motor rotating at 60 
mms-1 and moving horizontal oscillating speed 10 mms-1. 
 Characterization 
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) analyses 
were carried out using a Philips XL30 field emission scanning electron microscope and a 
Tecnai12 transmission electron microscope. Fibre diameter was measured using 
Microstructure Measurement software. For each sample, 100 measurements were carried out 
and the mean fibre diameter determined. IR spectra in transmission mode were collected using 
87 
 
a Thermo Nicolet 6700 FTIR Spectrometer. TGA was performed using a Netzsch STA 449 F1 
Jupiter TGA analyser at a heating rate of 10 °C/min under a nitrogen purge of 40 ml/min. 
Nitrogen adsorption-desorption isotherms were determined using a Micrometrics Tristar 3000 
BET surface area analyser (Micrometrics, USA). Pore volumes and pore sizes of the MSN 
were determined from the desorption branches of isotherms by the Barrett-Joyner-Halenda 
(BJH) method. The specific surface area was calculated according to the Brunauer-Emmett-
Teller (BET) method [34, 41, 42].  
 In Vitro Drug Release  
The electrospun mats were cut into circular discs (14.3 mm in diameter). Four discs were 
weighted then placed in a glass vial containing 10 mL of phosphate buffer saline solution (PBS, 
100 mM, pH 7.4) and were shaken continuously for 14 days at 150 rpm at 37◦C. At various 
time intervals 1mL of release medium removed and replaced with an identical fresh buffer. The 
UV absorbance of LVF in buffer solutions was measured at 290 nm and converted to the LVF 
concentration according to the calibration curve. The amount of released LVF was calculated 
from the LVF concentration at each time points.  
 Antimicrobial Assay 
Quantitative antimicrobial assays on the electrospun composite mats were carried out as per 
AATCC Test Method 100-1999 using E.coli (ATCC 4352) as the test species.  
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3.4 Results and Discussion 
 FTIR 
MSN were first loaded with the antibiotic before they were incorporated in the core regions of 
nanofibres. FTIR was used to confirm the presence of the LVF in the MSN complex [34, 43]. 
The spectra of LVF, MSN and LVF-MSN were collected and shown in Figure 3-2 
Characteristic FTIR transmission peaks of LVF were observed at 1294 cm-1 assigned to 
stretching of amines, 1620 cm-1 for aromatic C-C ,1724 cm-1 due to the presence of C=O and 
broad peak at 3265 cm-1 representing O-H of carboxylic acid group. No distinctive peaks were 
observed in the MSN spectra except for a strong peak at 1025 cm-1 due to the Si-O2 stretching. 
LVF-MSN exhibits a peak of carboxyl at 1717cm-1. This peak was slightly shifted from 1724 
cm-1due to the hydrogen bonding of the carbonyl of the LVF to the silanol groups [34]. The 
broad peak at 3350 cm-1 is present in LVF-MSN due to the carboxylic group of LVF. It also 
shows another peak at 1619 cm-1 due to the aromatic C-C which is present in LVF (Figure 3-3. 
inset). The peaks observed in the spectra of LVF-MSN confirm that LVF was present in MSN 
mesoporous structure.  
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Figure 3-2 FTIR Spectra of LVF, MSN and LVF-MSN. The inset graph is an enlargement of 3 spectra overlay in the 
region of 1200-1800 
 Nitrogen Adsorption Studies 
The drug loaded MSN were further characterized by nitrogen adsorption-desorption studies. 
The surface area, the total pore volume and the average pore diameter size were calculated 
from the nitrogen adsorption-desorption isotherms using the BET and BJH method. Figure 3-
3 shows typical IV isotherm curves for both MSN and LVF-MSN which confirm the existence 
of a uniform mesoporous structure [29]. The values for the BET specific surface area (SBET), 
the total pore volume (Vp) and the BJH pore diameter (Dp) are given in Table 3-1. 
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Figure 3-3 Nitrogen isotherms of MSN and LVF-MSN 
The BET surface area and average pore size of the MSN before loading LVF are 690m2g-1 and 
4.06nm. These parameters were decreased after loading LVF into MSN to 463m2g-1 and 3.5 
nm, respectively, in the case of LVF-MSN (Table 3-1). This indicates that the pores in MSN 
have been partially filled after loading with LVF thereby producing smaller values once the 
LVF is absorbed and occupying some of the volume and area that was previously available.   
Table 3-1 Surface area, pore size and pore volumes of MSN and LVF-MSN 
 
Surface area 
SBET (m2g-1) 
Pore size 
Dp (nm) 
Pore volume 
Vp (cm3g-1) 
MSN 690 4.06 0.74 
LVF-MSN 463 3.50 0.53 
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 TGA 
The overall amount of loaded LVF was estimated by TGA. In the TGA measurement, the drug 
desorbs after decomposing, which is detected as a temperature -dependent weight reduction. 
Together with BET and BJK measurements, TGA provides further evidence that the LVF is 
adsorbed into the MSN structure [44, 45]. As shown in Figure 3-4, the loading fractions were 
estimated from the mass loss ratio between 0 and 700°C compared to the total initial weight. 
No weight loss was observed in TGA of MSN as expected due to the high melting point of the 
MSN (>1600°C) [34]. Conversely, the weight loss due to drug uptake was around 20% for the 
weight of the LVF-MSN. These results, together with that of FTIR, BET and BJK 
measurements confirm that LVF had been successfully adsorbed into the MSN porous 
structure. 
 
Figure 3-4 TGA of LVF, MSN and LVF-MSN 
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 Architecture of Electrospun PCL/LVF and PCL/LVF-MSN Mats 
The architecture and nanofibre diameters of the electrospun mats with average diameter sizes 
of 600-700nm are shown in Figure 3-5 (A-H). Fibre size had a normal type distribution, with 
an average diameter of 600-900 nm (24%) for PCL/LVF-MSN and 500-800 nm (23%) for 
PCL/LVF. The results showed that the addition of MSN marginally increased fibre diameter. 
This is probably due to the increase in core solution viscosity as has been reported in different 
studies [29, 46]. Figure 3-5(E-F) show the TEM images of the structure of core-shell PCL/LVF 
and PCL/LVF-MSN composite nanofibres, respectively. The core-shell structure of the 
LVF/PCL nanofibrescan be easily observed; the red arrows indicate the boundaries of the shell 
and core layers. In the case of PCL/MSN-LVF composite mats as it can be observed from the 
Figure 3-5(B&D), there are no LVF-MSN complexes observed on the surfaces of nanofibres 
which means the confinement of the LVF-MSN complexes in the core region (Figure 3-5 F).   
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Figure 3-5 SEM images of electrospun core-shell PCL/LVF mat (A-B) and PCL/LVF-MSN mat (C-D), TEM 
images of core-shell PCL/LVF (E) and PCL/LVF-MSN mats (F), Fibre diameter distribution of PCL/LVF (G) 
and PCL/LVF-MSN (H) 
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 EDX Analysis 
The EDX analysis of the composite nanofibres was carried out in order to investigate the 
distribution of MSN (Si element) in the electrospun fibres. The elemental analysis reveals the 
presence of Si distributed through the mats. The elemental ratio of C, O and Si are 83, 16.3 and 
0.7% in the composite PCL/MSN composite nanofibres (Figure 3-6a). The layered SEM image 
(Figure 3-6b) shows even distribution of Si throughout the composite nanofibres.  
 
Figure 3-6 EDX spectrum (a) and MSN (Si) distribution (b) of electrospun core-shell PCL/MSN composite 
nanofibres 
 Cumulative Release of LVF  
Firstly, the release of LVF from drug-loaded MSN was measured separately to discover how 
long can MSN retain the drug. LVF release was measured by shaking the LVF-MSN in PBS 
solution at 37°C. Figure 3-7 shows that approx 70% of LVF in the nanoparticles was released 
in the first 20 min. The release plateaued by 60 min and there was little further release in the 
next 60 min. The MSN showed the ability to retain the antibiotic in the matrix for a short period 
of time with a burst release fashion. Similar release profiles have been previously reported. The 
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burst release of resveratrol was observed by Tsai et al, with 80% of the drug released in the 
first 10 min from resveratrol-MSN complexes. This indicates the drug was physically adsorbed  
into MSN [30].  
 
Figure 3-7 The cumulative LVF release from LVF- MSN 
In this study, the release of LVF from PCL/LVF, core-shell PCL/LVF, core-shell PCL/LVF-
MSN composite nanofibres and PCL/LVF films were measured by shaking in PBS solution at 
37°C. It was envisaged that the combination of MSN particles and the core-shell structure of 
the nanofibres would further modify burst release to provide drug release over a longer term. 
Figure 3-8 shows the release profiles of the LVF from uniform and core-shell nanofibres, and 
from the core-shell nanofibres where the drug had been adsorbed on MSN. The control 
PCL/LVF film was also included for comparison. The control PCL/LVF electrospun mat 
showed a strong burst nature, releasing 60% of the antibiotic in the first 24 h. Core-shell 
structure of the nanofibres slowed the initial release to 45% in the first 24 h. This observation 
is presumably due to the confinement of the drug in the core section of the nanofibres and the 
outer layer serving as a diffusion barrier [47]. In this study, although the initial release rates 
were quite different between control and core-shell nanofibres, both types of nanofibres 
released the same amount of the drug by 14 days (Figure 3-8).  On the other hand, the release 
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profile of core-shell PCL/LVF-MSN was different to the nanofibres without MSN. It has been 
reported that presence of loaded nanoparticles in uniform nanofibres influences the release 
kinetics and could reduce the burst release [29, 48]. Experimental evidence shows a 39% 
release after 24 hrs and gradually increased to 69% after 14 days. This suggests that the LVF 
releasing behaviour was considerably influenced by the MSN incorporated within the core of 
the core-shell nanofibres. On the other hand, the control PCL/LVF film showed only a 15% 
release of LVF in first 6 hr, and then remains largely unchanged. Distinctive differences 
between the release rates of control film and electrospun mats clearly demonstrates the 
advantages of nanofibres over flat film such as the high surface area of nanofibres that plays a 
significant role in  the release behaviour [49, 50].  
 
Figure 3-8 The cumulative LVF release from: PCL/LVF, Core-shell  PCL/LVF,  PCL/LVF-MSN  electrospun 
mats and PCL/LVF film.  
 Antibacterial Activity Assay  
The antibacterial properties of the various controls and core-shell electrospun mats were 
investigated quantitatively using E. coli reduction assays. E. coli is a Gram-negative bacterium 
that is commonly found in the lower intestine of warm-blooded organisms [40]. The assay was 
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done on samples after each time point in the cumulative release experiments. As expected, the 
control PCL electrospun mats containing no LVF showed no bacterial reduction. Both core-
shell electrospun mats showed antibacterial ability with greater than 99% bacterial reduction 
after 7 days (Figure 3-9). This antibacterial behaviour of two core-shell electrospun mats can 
be attributed to the burst release of the drug in first few days of immersion in PBS where the 
majority of the drug content was released [49, 50]. 
Core-shell PCL/LVF nanofibres displayed significantly lower efficacies in bacterial inhibition 
compared to core-shell PCL/LVF-MSN nanofibres after day 10 where they have lost most of 
its LVF content (see Figure 3-8); bacterial reduction was decreased after that to 72% after 14 
days. Conversely for the core-shell PCL/LVF-MSN nanofibres remained active and still 
showed bacterial inhibition after 7 days and roughly the same antibacterial ability after 14 days 
which is due to the reduced release rate.  
 
Figure 3-9 Antimicrobial assays of core-shell PCL/LVF, core-shell PCL/LVF-MSN and untreated PCL electrospun mats 
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  Conclusion   
This chapter describes the fabrication and characterization of composite nanofibres for 
sustained drug release. The material combines loading the drug, LVF, into mesoporous silica 
nanoparticles and confining them to the core of bilayer nanofibres using core-shell 
electrospinning. Such an approach significantly reduced the release rate from burst release to 
a sustained release beahviour over two weeks in a phosphate buffer. As a result, the composite 
nanofibres exhibited strong antimicrobial activity even after they had been soaked in a 
phosphate buffer for 14 days. The findings show that physical adsorption of a drug on a 
nanostructure and constraining them in the shell of bilayer nanofibres provides an effective 
means of achieving sustained drug release.  
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4 Chapter 4 
 
 
 
 
 
 
SLOW RELEASE OF LEVOFLOXACIN 
CONJUGATED ON MSN FROM PCL NANOFIBRES 
The paper submitted for publication in the International Journal of Polymeric Materials in 
based on the work described in this chapter. The slow release of LVF was achieved by 
combining two approaches. First is covalently binding LVF to MSN (as a biocompatible 
nanocarrier) via cleavable bond. Conjugated LVF-MSN was then confined into biodegradable 
PCL nanofibres in second approach by electrospinning.  
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4.1 Abstract 
A number of drug-nanofibrous composite mats have been reported as drug delivery systems. 
Their main disadvantage is a burst release of the drug.  This section of the thesis presents 
experimental results which demonstrate new approaches to obtain more appropriate release of 
Levofloxacin (LVF) from composite nanofibres.  Slow release was achieved through two 
approaches. The first approach is covalently binding LVF to the mesoporous silica 
nanoparticles (MSN) via a cleavable thioester bond and second approach is mixing the LVF 
conjugated MSN into poly(ɛ-caprolactone) (PCL) nanofibres. PCL/LVF nanofibrous mats 
were also fabricated as controls for comparison as in the previous chapter. The conjugated 
LVF-MSN was characterized by IR, DSC and solid-state 13C-NMR. After electrospinning, 
scanning electron microscopy (SEM) revealed the presence of MSN confined in the PCL 
nanofibres. Drug release profiles showed that release behaviour was decreased from 59% for 
the control PCL/LVF electrospun mats to 20% for the PCL/conjugated LVF-MSN mats after 
1 day in phosphate buffer at 37C, and continued gradual release was observed over the next 
13 days in the latter. This slow release of the LVF is due to the cleavable bond between LVF 
and MSN which can be hydrolysed over a time.  The results indicate that conjugation of the 
drug to MSN and confining them into nanofibres is a very effective way of minimizing burst 
release and achieving sustained release of the drug. 
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4.2 Introduction 
Sustained release systems of drugs have been widely explored due to their advantages in 
improving therapeutic efficiency and reducing toxicity by delivering the drug at a controlled 
release rate consequently overcoming adverse side effects [1-3]. The requirements for drug 
delivery carriers are: biodegradable, protect the drug from undergoing decomposition while 
providing a controlled release of the drug. In the past decade several drug carriers have been 
investigated such as cast films[4], micro- and nanoparticles [5, 6] and nanofibres [7]. Among 
these forms, nanofibres show the most promise [8]. Nanofibres are fabricated by 
electrospinning and used in various applications such as filtration [9, 10], nanocomposites [11, 
12] and medical textiles [13-15]. Electrospun nanofibres have been considered as drug delivery 
systems due to their advantages especially high surface area to mass ratio [14, 16, 17]. 
However, a disadvantage of drug loaded nanofibres has been the burst release behaviour of the 
drug that occurs where a large portion of the loaded drug is released in the first several h [18-
21]. The drug release profile of electrospun nanofibres is dependent upon the drug 
concentration and its distribution throughout the nanofibre volume as well as surface area. The 
reasons for the burst release behaviour may include the presence of the drug on the surface of 
nanofibres, instead of throughout the fibre volume and the fast degradation rate of the polymer 
[14, 22, 23].   
For drug-nanofibre systems to become useful it is necessary to slow drug release over a certain 
time period. One approach reported in the literature to reduce the burst release and prolong 
drug release is to employ drug (physically) loaded nanoparticles incorporated within the 
nanofibres [24-26]. In the past decade, a variety of biocompatible nanoparticles, including 
polymeric nanoparticles and silica nanoparticles, have been adopted as drug delivery 
applications [27-30]. Mesoporous silica nanoparticles have found widespread application in 
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drug delivery systems due to their high specific surface area, adjustable pore size, high pore 
volume and the presence of reactive groups. The reactive groups provide the opportunity to 
further functionalise the material (i.e. covalent conjugation to a drug) to allow better control of 
drug release [31, 32]. Numerous reports have been published on slow release of drugs from 
mesoporous silica nanoparticles [33-36]. For example, slow release of telmisartan from amine 
functionalised silica nanoparticles which is due to the strong interaction between the amine 
groups of MSN and carboxylic groups of drug has been reported [37]. Another approach is to 
covalently bind a drug to the nanocarriers via a cleavable bond. For example, doxorubicin 
(DOX) was chemically conjugated to poly(lactic-co-glycolic acid) (PLGA) by a cleavable 
linkage and then converted into nanoparticles [38]. The conjugated DOX-nanoparticles 
exhibited sustained DOX release profiles over 30 days whereas nanoparticles containing free 
DOX (unconjugated) showed a much faster release over 5 days as a result of simple drug 
diffusion through the matrix. This improved release profile was due to the slow and controlled 
hydrolysis of the ester linkage between DOX and PLGA over time.  
The aim of this study was to design one sustained drug delivery system with a combination of 
different drug release mechanisms. The new system is based on the covalent binding of the 
drug to the nanocarriers and then incorporating the conjugated nanocarrier into a biodegradable 
polymer nanofibres ie poly(ɛ-caprolactone) (PCL). PCL was chosen as the carrier polymer 
because of its biocompatibility, electrospinnability and slow degradation rate (up to 24 months) 
[39]. Levofloxacin (LVF) was conjugated to propylthiol functionalised mesoporous silica 
nanoparticles (MSN), fabricated into a nanofibre/MSN composite and the release profile from 
the electrospun composites measured and compared to the composite nanofibres/control LVF-
MSN (non-conjugated) and control drug blended electrospun nanofibres. 
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4.3 Materials and Methods 
 Materials 
Poly(ɛ-caprolactone) (PCL, MW 80000 g/mol), propylthiol functionalised mesoporous silica 
nanoparticles (200 nm particle size and 4 nm pore size), levofloxacin (98.0%), dichloromethane 
(DCM) and N,N-dimethylformamide (DMF) were sourced from Sigma-Aldrich. 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) was purchased from Pierce. Dimethylsulfoxide 
(DMSO) was supplied by Fisher Chemical and 2-(N-morpholino)ethanesulfonic acid (MES) 
from Fluka. All other chemicals were of reagent grade and used without further purification. 
 Methods 
 Preparation of Conjugated LVF-MSN and PCL/LVF-MSN Nanofibres 
LVF (100 mg ) and EDC (56 mg) (1:1 molar ratio) were dissolved in 1 mL DMSO and mixed 
for 30 min to activate the LVF [40, 41]. The activated LVF solution was then slowly added to 
5 mL of 100 mM PBS solution containing 100 mg of MSN and stirred continuously for 8 h. 
The conjugated nanoparticles were collected after centrifugation (15 min, 16000 g), dispersed 
in 5 mL of deionised water and sonicated for a further 5 min to remove unbound LVF. The 
MSNs were finally collected after centrifugation and dried at room temperature for 48 h. The 
control LVF-MSN without conjugation was prepared by mixing LVF and MSN for 8 h in 
deionised water and then collected by centrifugation.  
Electrospun mats were prepared containing 1 wt% of LVF, 4 wt% of LVF-MSN (with respect 
to PCL).  For polymer solutions, 30 mg LVF, 120 mg conjugated LVF-MSN and 120 mg 
control LVF-MSN were added to three separate bottles containing 20 g of 15 wt% PCL in a 
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1:1 (by weight) mixture of DCM:DMF and stirred continuously until a homogeneous solution 
was obtained.  
The basic experimental setup for the electrospinning process is shown in Figure 4-1. The setup 
contained a spinneret needle (23 G Terumo), syringe pumps (model NE-1000 New Era Pump 
Systems, Inc., Farmingdale, NY, USA), a high voltage supply (Spellman high voltage DC 
power supply, USA) and a 5 mL syringes (Terumo). The electrospinning distance was varied 
between 0 and 300 mm (optimised distance of 150 mm) and applied voltage was varied 
between 0 and 40 (optimised value of 15 kV). Electrospun mats were collected for 10h on a 
drum collector of 100 mm diameter. 
 
Figure 4-1 Schematic diagram of preparation of LVF-MSN and PCL/LVF-MSN nanofibres. 
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 Characterization  
Scanning electron microscopy (SEM) analyses were carried out using a Philips XL30 field 
microscope. Fibre diameters were measured using the microstructure measurement software. 
For each sample, 100 measurements were taken to obtain an average fibre diameter. IR spectra 
were collected in the transmission mode using a Thermo Nicolet 6700 FTIR Spectrometer. The 
specific surface area and pore characteristics of the MSN were determined according to the 
Barrett-Joyner-Halenda (BJH) and Brunauer-Emmett-Teller (BET) method [42, 43]. DSC 
analysis of samples was carried out at a heating rate of 10°C/min under a nitrogen purge of 
40ml/min using a Netzsch STA 449 F1 Jupiter DSC Thermal Analyser. TGA was performed 
using a Netzsch STA 449 F1 Jupiter TGA Thermal Analyser at a heating rate of 10°C/min 
under a nitrogen purge of 40ml/min. Solid-state 13C cross-polarization (CP-MAS) NMR 
spectra were recorded on a Bruker AV500 MAS spectrometer. A Varian UV-Vis 
spectrophotometer was used to measure the LVF concentration at 290 nm. 
 In Vitro Drug Release 
The electrospun mats were cut into squares of 50x50 mm. Each square was weighed and then 
placed in 5 mL of phosphate buffer saline solution (PBS, 100 mM, pH 7.4) and shaken 
continuously for 14 days at 150 rpm at 37°C. 2mg of control and conjugated LVF-MSN placed 
in 5 mL of phosphate buffer saline solution (PBS, 100 mM, pH 7.4 and pH 9.0) and shaken 
continuously for 2 h at 150 rpm at 37°C. At each time points 1mL of release medium removed 
and replenished with an identical fresh release buffer. The UV absorbance of LVF in buffer 
solutions was measured at 290 nm and converted to the LVF concentration according to the 
calibration curve. LVF release profiles were calculated from the LVF concentration at each 
time point.  
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4.4 Results and Discussion 
A novel drug delivery composite was formed by conjugating LVF to MSN then incorporating 
them into PCL nanofibres fabricated by electrospinning. LVF was used as a model drug 
because it is a common antibiotic with a carboxylic acid group that can be used for further 
chemical modification (i.e. conjugation) and has a chromophore for easy detection at max of 
290 nm. The funtionalised LVF/MSN and control were characterised and the LVF release 
profiles were measured. 
 FT-IR 
FT-IR spectra of LVF, MSN, control LVF-MSN and conjugated LVF-MSN are shown in 
Figure 4-2. Characteristic IR transmission peaks of LVF can be observed at 1294 cm-1 from 
amines, 1620 cm-1 due to aromatic C-C bonds, 1720 cm-1 due to carboxyl group C=O and the 
broad peak at 3265 cm-1 from the O-H of the carboxylic acid. Spectra of MSN show a strong 
peak at 1025 cm-1 due to Si-O2 stretching. In the control spectra of LVF-MSN a peak at 1712 
cm-1 was observed due to the hydrogen bonding of the silanol groups and carboxylic groups of 
LVF (Figure 4-2c) [37]. There are also absorption band(s) at 3350 cm-1 due to the presence of 
hydroxy groups of unbound LVF in the control LVF-MSN. This was not observed in the 
spectrum of the conjugated LVF-MSN; indicating a reduction of hydroxy group stretching after 
conjugation. The absorption at 1703 cm-1 in the conjugated LVF-MSN is due to the formation 
of the thioester bond between LVF and thiol moieties [44, 45]. 
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Figure 4-2 FT-IR Spectra of LVF (a), MSN (b), Control LVF-MSN (c) and conjugated LVF-MSN (d). 
 DSC 
DSC analysis was used to determine the absence of the crystalline drug in the conjugated LVF-
MSN form which is indicative of bound LVF instead of free LVF, resulting in no melting point 
depression for the LVF in the non-crystalline state [46-48]. As shown in Figure 4-3a the DSC 
curve of LVF exhibited one endothermic peak at 100°C due to the dehydration of LVF [49] 
and one peak at 244°C representing its melting point. No peak was detected in the MSN 
thermogram due to its high melting point (1600-1725°C) [37, 47]. The melting peak of LVF 
was observed to shift slightly from 244°C to 229°C in the control LVF-MSN. The absence of 
phase transition point(s) of LVF in the conjugated LVF-MSN thermogram is due to the 
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presence of LVF in a non-crystalline, amorphous state or disordered-crystalline state after LVF 
and MSN are conjugation [50, 51].  
 
Figure 4-3 DSC thermograms FT-IR Spectra of LVF (a), MSN (b), Control LVF-MSN (c) and conjugated 
LVF-MSN (d). 
 TGA 
TGA is an important method to quantify the amount of loaded drug [37, 52].  In the TGA 
measurement, the drug desorbs after decomposing, which is detected as a temperature 
dependent weight reduction. As shown in Figure 4-4, the loading fractions in all cases were 
estimated from the ratio of the weight loss between 0 and 700°C to the total initial weight. The 
weight loss of MSN is 13.1% due to the loss of functional groups of MSN, respectively. The 
weight loss due to drug uptake was 29.4% for the control LVF-MSN and 26.3% for conjugated 
LVF-MSN.  The drug uptake values obtained by TGA were in agreement with those obtained 
by nitrogen adsorption studies in next section, as shown in Table 4-1.  
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Figure 4-4 TGA of  LVF , MSN , Control LVF-MSN and conjugated LVF-MSN. 
 Nitrogen Adsorption Studies 
The mesoporous structure of the various version of the MSNs were further characterized by N2 
adsorption-desorption isotherms. Figure 4-5 shows typical IV isotherm curves for MSN, the 
control LVF-MSN and conjugated LVF-MSN. The isotherm confirm the existence of uniform 
mesoporous [28]. The BET surface area and the average pore size of the thiol derived MSN 
decreased from 640 m2g-1 and 4.8 nm to 541 m2g-1 and 4.17nm, respectively, in conjugated 
LVF-MSN and 534 m2g-1 and 4.20 nm in control LVF-MSN. These indicate that LVF was 
loaded into the pores in both samples [37].  
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Figure 4-5 Nitrogen isotherms of MSN and control LVF-MSN and conjugated LVF-MSN 
Table 4-1 Structural parameters of MSN and control LVF-MSN and conjugated LVF-MSN 
 SBET (m2g-1) Dp(nm) Vp(cm-3g-1) 
MSN 640 4.8 0 .77 
Conj LVF-MSN 541 4.17 0.60 
Ctrl LVF-MSN 534 4.20 0 .56 
 
 NMR 
Solid state 13C NMR was also used to confirm the conjugation of LVF to the MSN (Figure 4-
6). The spectrum of MSN , Figure 4-6a, showed chemical shifts at 15.5, 23.5 and 26.8 ppm 
corresponding to the propyl carbons (Ci,Cii and Ciii) [53]. The shifts with asterisk (*) at 10.8 
ppm and at 59.5 ppm were assigned to the presence of ethanol which was used as a stabilising 
agent in the supplied MSN (MSN was used as received). In the spectrum of the conjugated 
LVF-MSN, Figure 4(d) the shifts of carbonyl carbons (C15 and C16) are different from those of 
control LVF-MSN; C16 changed to 160.3 ppm and C15 to 171.6 ppm as a result of thioester 
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bond in the conjugated LVF-MSN. Similar changes in shifts have been reported in the literature 
whereby the shift of thioester carbonyl carbon had a higher value than other carbonyl carbons 
[54, 55]. Also, in the spectrum of the conjugated LVF-MSN, Figure 4-6d, the propyl C adjacent 
to the S changed from 23.5 ppm to 35.3 ppm.  Similar shifts have been observed reactions with 
propyl thiols after conjugation due to the different cross-polarization dynamics of propylthiol 
carbons [56].  
 
Figure 4-6 Solid state NMR spectra of LVF (a), MSN (b), control LVF-MSN (c) and conjugated LVF-MSN (d). 
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 Morphology of Electrospun Mats 
The morphology and fibre diameter distributions of the electrospun mats are shown in Figure 
4-7(a-f). Fibre diameter distribution followed a normal type distribution. The addition of MSN 
increased the average fibre diameter compared to the control PCL nanofibres from 0.6 µm to 
0.8 µm in PCL/LVF-MSN composite mats, Figure 4-7 (c&f). This increase in average fibre 
diameter was probably caused by the increase in solution viscosity after the addition of MSN 
[57]. Figure 4-7(d-e) also shows the smooth surface of PCL/LVF electrospun nanofibres. 
However, after adding MSN, the composite electrospun nanofibres appeared to become rough 
with particles clearly noticeable on the surface of the nanofibres (Figure 4-7a&b). This 
phenomenon is due to the aggregation of MSNs particles in the PCL solution formed during 
electrospinning or the incomplete dispersion during the initial dispersion process into the PCL 
solution [26]. 
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Figure 4-7 SEM images of electrospun PCL/LVF-MSN mat (a-b) and PCL/LVF (d-e); Fibre diameter 
distribution of PCL/LVF-MSN (c) and PCL/LVF (f) nanofibres. 
 EDX Analysis  
EDX analysis was carried out in order to investigate the content and distribution of MSN (Si 
element) in PCL/LVF-MSN composite mats. As it’s shown in Figure 4-8 (left) EDX data from 
the area analyses of the nanofibres shows the presence of Si with ratio of 1 wt% which 
corresponds to the presence of MSN distributed in nanofibres. Figure 4-8 (right) shows even 
distribution of MSN (Si element) through nanofibres. As previously mentioned in SEM images 
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(Figure 4-7A&B) the aggregation of MSNs in nanofibres can be also observed in EDX layer 
image.  
 
Figure 4-8 EDX spectrum (left) and MSN (Si) distribution (right) of electrospun PCL/LVF-MSN composite 
nanofibres 
 Cumulative Release of LVF 
The release of LVF was measured in the control and conjugated LVF-MSN to measure if 
functionalized MSN could retain the LVF drug. The release of LVF from the nanoparticles was 
performed at different pHs (pH 7.4 and pH 9.0) in order to observe the influence of pH on the 
hydrolysis of thioester bonds in conjugated LVF-MSN. More release of LVF was expected to 
occur under conditions that promote the hydrolysis of thioester bond i.e. pH9.0 than compared 
tp pH7.4 [58]. As shown in Figure 4-9, LVF is released from conjugated LVF-MSN in basic 
medium to a higher extent, 90% of LVF released in 120 min than in at pH 7.4 with 74% of 
LVF released. In the control LVF-MSN 82% of LVF content was released (pH 7.4) in the first 
20 min with the release plateauing by 60 min with no further release observed after 60 min. 
The LVF release profile of control LVF-MSN in pH 9.0 shows roughly the same release profile 
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of control LVF-MSN in pH 7.4 as a result of no stable chemical binding between LVF and 
MSN that can be affected by pH level.  
 
Figure 4-9 The cumulative LVF release from control LVF-MSN and conjugated LVF-MSN at pH 7.4 &  9.0.  
The same release profile of LVF from MSN was observed in our previous study where LVF 
alone was blended with MSN [59]. This shows that MSN can retard LVF release in the matrix 
for a short period of time most likely due to the formation of weak hydrogen bonds between 
LVF and silanol groups on MSN [37, 60] . The slower release profile of the LVF from the 
conjugated LVF-MSN is attributed to the covalent binding (conjugation) of the LVF and MSN 
through the thioester bond followed by the hydrolysis of the thioester bond in alkaline medium 
[58, 61]. 
Figure 4-10 shows the release profiles of the LVF from the control and two composite 
nanofibres; one with drug adsorbed into the MSN (control LVF-MSN) and the other with drug 
covalently attached to the MSN. It was envisaged that the combination of conjugation and 
nanofibres would further slow burst release to provide drug release over a longer time period. 
The control PCL/LVF electrospun mat showed a strong burst nature, releasing 59 % of the drug 
in the 24 h. This fast release of LVF was attributed to a simple diffusion process of the drug 
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through the matrix of PCL nanofibres [38]. The adsorption of LVF on MSN (control LVF-
MSN) in the nanofibres slowed the initial release of LVF to 42 % in the first day. The mitigation 
of the burst release of a drug from drug-nanoparticles composite nanofibres has been reported 
in the literature [26, 62-64]. For example, Song et al fabricated polylactic-glycolic acid/MSN 
composite mats for prolonged release of fluorescein [65]. They found the burst release of 
fluorescein was reduced compared to uniform drug loaded nanofibres. On the other hand, the 
release profile of PCL/conjugated LVF–MSN composite nanofibres was different to the other 
two nanofibres. The release was 20% after 1 day and gradually increased to 51% after 14 days. 
This indicates that LVF releasing behaviour was considerably influenced by covalent binding 
between LVF and MSN that can be cleaved due to the selective hydrolysis of the thioester bond 
[58, 61]. Ibuprofen conjugated polyethylene glycol hydroxyethyl thioester (PEG-HET) was 
fabricated by Davaran et al and slow release behaviour of ibuprofen was reported due to the 
hydrolysis of thioester bond between ibuprofen and hydroxyl ethyl thiol [58]. 
 
Figure 4-10 The cumulative LVF release from PCL/LVF, PCL/Control LVF-MSN and PCL/Conjugated LVF-
MSN electrospun mats. 
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4.5 Conclusion 
This chapter follows on from the previous chapter and describes a composite nanofibrous 
material which exhibits sustained drug release behaviour. The new material is formed through 
covalently binding the carboxyl group of the LVF to thiol functionalised MSN through the 
formation of a thioester bond. Characterisation was confirmed prior to spinning 
electrospinning. Such an approach significantly reduced the burst release property of the drug 
and led to a sustained release over 2 weeks in phosphate buffer. The findings show that 
chemically binding of a drug to a nanocarrier and distribution of the nanocarrier in the form of 
nanofibres provides a highly effective means of achieving sustained drug release efficacy due 
to cleavable bond between drug and nanocarrier that can be broken  by hydrolysis attack in 
buffer solution.  
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5 Chapter 5 
 
 
 
 
 
 
SLOW RELEASE OF LVF FROM PVA/CONJUGATED 
CHITOSAN COMPOSITE NANOFIBRES 
This Chapter has formed the basis of a paper submission to the Journal of Controlled Release 
in March 2016. LVF was conjugated to chitosan and then blended into PVA solution and then 
composite nanofibres were electrospun. The new drug-polymer composite nanofibres showed 
superior release behaviour of highly soluble PVA nanofibres. 
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5.1 Abstract 
Various drug-nanofibrous composite mats have often been reported as drug delivery systems. 
Their main disadvantage is burst release of drug immediately after application. The aim of this 
chapter was to fabricate composite nanofibrous mats based on the incorporation of chitosan to 
which LVF had been covalently bound. The study showed that controlled release of 
levofloxacin (LVF) could be achieved by covalently binding LVF to low molecular chitosan 
(CS) via a cleavable amide bond and then blending the conjugated CS with polyvinyl alcohol 
(PVA) nanofibres prior to electrospinning. PVA/LVF and PVA-CS/LVF nanofibrous mats 
were also fabricated as controls. The conjugated CS-LVF was characterised by FTIR, DSC, 
TGA and 1H-NMR. Scanning electron microscopy (SEM) revealed that the blended CS-PVA 
nanofibres decreased the fibre diameter compared to control PVA nanofibres. Drug release 
profiles showed that burst release was decreased from 90% in the control PVA/LVF 
electrospun mats to 27% in the PVA/conjugated CS-LVF mats after 8 h in phosphate buffer at 
37C, and gradual release in the latter was observed over the next 72 h. This slow release is 
due to the cleavable bond between LVF and CS that slowly hydrolysed over time at neutral 
pH. The results indicate that conjugation of the drug to the polymer backbone is an effective 
way of minimizing burst release behaviour and achieving sustained release of the drug, LVF 
in this case. 
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5.2 Introduction 
Controlled slow release systems of drugs have been widely explored due to their advantages 
compared to other methods of drug administration [1, 2]. The advantages include reducing the 
side effects of general drug administration by delivering the drug at a controlled release rate, 
improved therapeutic efficiency, continuous sustained release of small amounts of drug instead 
of several large doses decreases side effects and improves of patient compliance [3]. In the past 
decade several drug delivery systems have been investigated for a controlled release of drugs 
from nanoparticles [4] and biodegradable nanofibres [5]. Also nanofibres have gained 
considerable attention as a drug delivery system in the last decade and have been proved to 
offer an efficient drug delivery system for providing sustained release of drugs [6, 7]. Various 
biodegradable nanofibres have been investigated for controlled release of drugs [8-10]. 
However, a major drawback of drug loaded nanofibres is the undesired burst release behaviour 
of drug from nanofibres  [11-14].  
For example, ciprofloxacin loaded nanofibres of poly(vinyl alcohol) (PVA) have been reported 
[14] with high initial burst release (80%) of total ciprofloxacin content in the first 40 h. The 
burst release of salicylic acid (SA) from poly(vinyl alcohol) nanofibres with different SA 
concentration was also reported [15]. The release profiles showed very high burst release 
within the first h with 40-65% of the total drug released and then increased rapidly after 10 h 
in all cases until reaching equilibrium with approximately 95% of total drug released. The burst 
release behaviour of the drugs may be due factors such as a large proportion of the drug on the 
fibre surface due to insufficient mixing and rapid drug diffusion out of the polymeric matrix 
because of fast polymer degradation [14, 16, 17]. 
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In order to obtain the controlled slow release profile desired it is necessary to overcome the 
initial burst release. One approach reported in the literature for achieving a controlled release 
of drug is covalent conjugation of drugs to the polymer backbones [18-20]. This approach 
requires the presence of functional groups on both the drug and polymer on which chemistry 
can be done. For example, docetaxel (DTX) was covalently attached to low molecular weight 
CS via a cleavable amide linker. Prolonged slow release of DTX was obtained in simulated 
intestinal fluid (pH 7.5) which resulted in higher bioavailability along with prolonged 
circulation time in the blood stream than the intravenously injected DTX [21]. In another study, 
composite nanofibres of poly(lactide-co-glycolide) (PLGA) and poly(ethylene glycol)-g-
chitosan-ibuprofen (PEG-g-CS-IBU) conjugates were fabricated by covalently linking IBU  to 
the amine groups of chitosan via amide bond [22].  There it was observed that presence of 
conjugated CS-IBU in the matrix reduced the burst release due to the cleavable amide bond 
between chitosan and ibuprofen. Another report includes synthetising of doxorubicin 
conjugated stearic acid-g-chitosan polymeric micelles (DOX–CS–SA) [23]. The release profile 
showed that release behaviour of DOX is pH-dependent where the release rate of DOX 
increased with the reductions of the pH for release medium from 7.2 to 5.0.   
PVA is widely used in biomedical applications due to its well-known characteristics such as 
biocompatibility, biodegradability, water solubility, nontoxicity, swelling capability in an 
aqueous medium, and appropriate mechanical properties [24-26]. It has been reported that by 
incorporating a second polymer component such as chitosan (CS) into the PVA solution, leads 
to an improvement in biocompatibility and mechanical properties (e.g. solubility) of the 
nanofibres. Chuang et al [27] fabricated PVA/CS blended membranes for cell culture. They 
observed that the PVA/CS blended membrane was more favourable for the cell culture with 
better spreading of cultured cells than the pure PVA membrane.  
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The aim of this chapter was to design a controlled drug delivery system by conjugating a LVF 
from the carboxylic groups to the amine groups of chitosan using carbodiimide chemistry [28, 
29], followed by mixing the conjugated system with PVA prior to electrospinning. This method 
was used in order to reduce the burst release of drug from highly water soluble PVA nanofibres 
which has been reported [14, 15]. The release profiles of PVA/CS-LVF electrospun composite 
mats were measured and compared to the control PVA/LVF and PVA-CS/LVF (non-
conjugated) electrospun composite mats. 
5.3 Materials and Methods  
 Materials 
PVA (MW 85,000-124,000, 98-99% hydrolysed), low molecular weight CS (deacetylation ≥ 
75%), LVF (98.0%) and acetic acid were all purchased from Sigma-Aldrich. 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) crosslinker was purchased from Pierce. Dimethyl 
sulfoxide (DMSO) was from Fisher Chemical and sodium hydroxide flake was from Chem 
Supply. All other chemicals were of reagent grade and used without further purification. 
 Methods 
 Synthesis of CS-LVF  
The conjugation of LVF and CS was based on the mechanism of carbodiimide chemistry [28, 
29]. CS (1g) was dissolved in 0.1M acetic acid solution (500mL). A mixture solution of LVF 
and EDC (1:1 molar ratio) was prepared by dissolving LVF and EDC in 10mL anhydrous 
dimethyl sulfoxide (DMSO). Then, the mixture solution was added dropwise to the CS solution 
under magnetic stirring continuously for 12 h. The conjugated CS was then coagulated by 
adding 1M NaOH to increase the pH level of the CS solutions. CS-LVF was collected by 
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centrifugation (15 min, 16000 g), washed by DI water and then dried at room temperature for 
24 h.  
 
Figure 5-1 The preparation of CS-LVF 
 Preparation of Composite Electrospun Mats 
Electrospun mats were prepared containing 1 wt% of LVF, and 5 wt% of CS-LVF (with respect 
to PVA).  For polymer solutions 20mg LVF, 100mg CS-LVF were added to two separate vials 
containing 20 g of 10 wt% PVA (dissolved in water) and stirred continuously until a 
homogeneous solution was obtained. A solution of 10 wt% PVA-CS (9:1) was also prepared 
with 1 wt% LVF (with respect to PVA-CS).  To obtain homogeneous solutions of PVA/CS, 
The pH of the PVA solution was adjusted to 6 by dropwise adding 1M HCL.  
The basic experimental setup for the electrospinning process is shown in Figure 5-2. The setup 
contained a spinneret needle (23 G Terumo), syringe pumps (model NE-1000 New Era Pump 
Systems, Inc., Farmingdale, NY, USA), a high voltage supply (Spellman high voltage DC 
power supply, USA) and a 5 mL syringes (Terumo). The electrospinning distance was varied 
between 0 and 300 mm (optimised distance of 150 mm) and applied voltage was varied 
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between 0 and 40 (optimised value of 12 kV). Electrospun mats were collected for 10h at 
0.6mL/h-1 pump rate on a drum collector of 100 mm diameter.  
 
Figure 5-2 Schematic diagram of preparation of CS-LVF and PVA/CS-LVF nanofibres 
 Characterization 
IR spectra were collected in the transmission mode using a Thermo Nicolet 6700 FTIR 
Spectrometer. DSC analysis of samples was carried out at a heating rate of 10°C/min under a 
nitrogen purge of 40ml/min using a Netzsch STA 449 F1 Jupiter DSC Thermal Analyser. TGA 
was performed using a Netzsch STA 449 F1 Jupiter TGA Thermal Analyser at a heating rate 
of 10°C/min under a nitrogen purge of 40ml/min. 1H NMR spectra of the samples were 
recorded on a Bruker Av400 NMR spectrometers. Scanning electron microscopy (SEM) 
analyses were carried out using a Philips XL30 field microscope. Fibre diameters were 
measured using the microstructure measurement software. For each sample, 100 measurements 
were taken to obtain an average fibre diameter. A Varian UV-Vis spectrophotometer was used 
to measure the LVF concentration at 290 nm. 
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 In Vitro Drug Release 
The electrospun mats were cut into squares of 50x50 mm. Each square was weighed and then 
placed in 5 mL of phosphate buffer saline solution (PBS, 100 mM, pH 7.4 and pH 5.0) and 
shaken continuously for 3 days at 150 rpm at 37°C. At each time points 1mL of release medium 
removed and replenished with an identical fresh release buffer. The amount of released LVF 
at each time point was determined by UV spectrophotometer. The UV absorbance of LVF in 
buffer solutions was measured at 290 nm and converted to the LVF concentration according to 
the calibration curve. LVF release profiles were calculated from the LVF concentration at each 
time points. 
5.4 Results and Discussion  
In this study we designed a novel drug delivery system in order to improve the release profile 
of highly soluble PVA nanofibres. The system is based on conjugating LVF to CS, combining 
them with PVA and then fabricating composite nanofibres by electrospinning. Again LVF was 
used as the model drug for its functional carboxylic acid group and ease of analytical detection 
by absorption at its peak at 290 nm.  
 FTIR 
FTIR spectra of LVF, CS and CS-LVF were obtained and shown in Figure 5.3. Characteristic 
FTIR transmission peaks of LVF can be observed at 1294cm-1 (assigned to stretching of 
amines), 1620cm-1 for aromatic C-C, 1720cm-1 due to carboxyl C=O and a broad peak at 3265 
cm-1 representing O-H of carboxylic acid.  The peak assignment of CS shows characteristic 
bands at 3351 cm-1  assigned to combined stretching of NH2 and OH groups,  1643 cm
-1 due to 
NH2 scissoring vibration, 1590 cm
-1 for carbonyl asymmetric stretching, and at 1028 cm-1 due 
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to the C-O of the pyranose ring [30, 31]. The conjugated CS-LVF spectrum shows a peak at 
1652cm−1 due to a secondary amide band (C–O stretch of acetyl group); and the peak at 1575 
cm-1  most likely due to N–H stretch of amide bond, confirming the formation of amide bond 
[29, 31-33]. 
 
Figure 5-3 FTIR spectra of LVF, CS and CS-LVF. 
 1H-NMR  
The conjugated CS-LVF was characterized and the formation of amide linkage between CS 
and LVF was confirmed by 1H-NMR spectroscopy. As shown in Figure 5-4, CS-LVF gave rise 
to a series of peaks at 4.60, 3.11, 3.90 and 3.72 ppm corresponding to 1H linked to the carbon 
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atoms in sugar ring (Ha, Hb, Hc, Hd, respectively) [33, 34]. The new signal appeared at δ=2.5–
2.7ppm corresponding to Ha due to the formation of an amide bond in between LVF and 
chitosan chains [34-36].   
 
Figure 5-4 1H-NMR sepectra of LVF, CS and CS-LVF. 
 DSC 
Thermograms of LVF, CS, and CS-LVF are presented in Figure 5-5. DSC analysis was 
conducted to determine the interaction of CS with LVF. The DSC thermogram of pure CS 
indicated one exothermic transition at 309.6ºC along with one endothermic transition at 
101.9ºC.  The exothermic transition is indicative of CS degradation at 309.6ºC and the 
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occurrence of an endothermic transition at 101.9ºC could be attributed to the moisture present 
in samples or the presence of acetic acid moieties [37-39]. The DSC thermogram of LVF 
showed endothermic transitions at 94.2ºC and 237.2 ºC due to the decomposition of LVF. The 
CS-LVF conjugate showed a new sharp endothermic transition at 250.5ºC that was neither 
present in thermogram of CS nor of LVF. This endothermic transition at 250.5ºC could be 
hypothesized to have arisen due to carboxylic linkage between -COO- moieties of LVF and -
NH3+ moieties of CS and formation of amide bond between LVF and CS [38]. 
 
Figure 5-5 DSC thermograms of LVF, CS and CS-LVF. 
 TGA 
The thermogram of CS exhibits two distinct stages of weight loss. One is in the range of 30–
107 °C due to the loss of adsorbed and bound water and decomposition of low molecular 
weights polymers (Figure 5-6). The second stage starts at 240 °C and continues up to 370 °C 
due to the degradation of chitosan biopolymer [40]. This stage is ascribed to dehydration of the 
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sugar rings, depolymerization and decomposition of the acetylated and deacetylated units of 
the polymer [41]. TGA spectra of the conjugated CS-LVF demonstrated slow weight loss at 
about 90 °C due to evaporation of water and moisture content in the polysaccharide. The 
second decomposition stage starts at about 195 °C which is lower than that of CS. The fast 
process of weight loss appears from 195 to 310°C. This is attributed to the thermal 
destabilization of the chitosan chains due to the conjugation of LVF in a polymer chain and 
related dissociation of the strong intra-molecular bonding [40, 42].  
 
Figure 5-6 TGA spectra of LVF, CS and conjugated CS-LVF 
 Morphology of the Nanofibres 
The morphology and fibre diameters of the electrospun mats with diameter sizes distributions 
are shown in Figure 5-7 (A-C). PVA electrospun nanofibres have uniform structure and fibres 
diameters compare to the PVA/CS composite nanofibres. The addition of CS in the 
electrospinning solution greatly influences the morphology of the electrospun nanofibres [43]. 
The fibre diameter distribution of the PVA/LVF nanofibres followed a normal distribution. 
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Incorporation of chitosan reduced the fibre diameter by approximately 50%. The average fibre 
diameters were marginally decreased from 200-300nm to 100-200nm. This reduction in 
diameter is due to the presence of CS a cationic polysaccharide with amino groups, which are 
ionizable under acidic conditions. It has been reported that the addition of cationic and anionic 
polyelectrolytes would affect the conductivity of polymer solution thus result in thinner fibre 
[44, 45]. 
 
Figure 5-7 SEM images of electrospun PVA/LVF (A), PVA-CS/LVF (B) and PVA/CS-LVF (C); and their 
relative diametere distribution.  
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 Cumulative Release of LVF 
Figure 5-8 shows the release profiles of the LVF from the controls and two composite 
nanofibres; one with CS/LVF in the composition and the other with drug covalently attached 
to CS (Conjugated CS-LVF). The uniform PVA/LVF electrospun mat showed an extreme burst 
nature, releasing 90% of the drug in the first 8 h. This very fast release behaviour of LVF was 
attributed to the swelling properties and dissolution of the PVA matrix within the medium. It 
has been reported that as soon as the PVA matrix began to swell, LVF molecules were leached 
out from the matrix very quickly [46, 47]. A similar phenomena has been reported by Kenawy 
et al [48]; they observed a fast burst release of ketoprofen from PVA with a release of about 
85.24% of the drug content within the first 2h.  
The amount of released LVF increases with decreasing pH value. As shown in Figure 5.8 the 
addition of CS in to PVA matrix only slightly reduced the burst release to 82% after 8 h in pH 
7.4. This indicated that addition of CS to the PVA matrix may have enhanced the swelling and 
dissolution properties of PVA [49]. The release profile of LVF from PVA-CS/LVF at pH 5.0 
shows a faster release than LVF due to faster dissolution of CS in acidic medium. In other 
words, incorporation of hydrophobic CS into PVA nanofibres decreased the diffusion and 
therefore the release from the nanofibres. A recent report shows that composite nanofibres of 
PVA and polyvinyl acetate could reduce the burst release of ciprofloxacin to 55% after 24 h 
from 82% in control PVA nanofibres [14]. On the other hand, the release profile of the 
PVA/conjugated CS-LVF nanofibres at pH 7.4 was significantly different to the other two 
nanofibres. The release was 27% after 8 h and gradually increased to 59% after 72 h. At pH 
5.0  it released 32% of LVF content after 8 h at pH 5 and reached to 85% after 72 h. This is 
due to the covalently grafted (via an amide bond) to CS. The release occurs first by CS 
dissociation and hydrolysis of amide bond from composite nanofibres and then by simple 
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diffusion. The cleavage of the amide bond depends on the pH value, the lower the pH value 
the faster hydrolysis of amide bond and higher drug release from the composite nanofibres 
containing conjugated chitosan [50]. These results indicate the notable stability of the amide 
bond in buffered solution (at pH 7.4) which resulted in limiting the diffusion rate of LVF in the 
matrix. A similar drug release profile has been reported  by Jiang et al [22]. Composite 
nanofibres of poly(lactide-co-glycolide) (PLGA) and poly(ethylene glycol)-g-chitosan (PEG-
g-CS) with ibuprofen (IBU) conjugated to CS were fabricated. They observed that the burst 
release of IBU from PLGA membrane dropped from 85% to 20% in PLGA-PEG-g-CS (IBU 
was covalently conjugated to the CS via amide bond) after 4 days. This slow release is due to 
the amide bond between IBU and CS  that can be cleaved in release medium. Another report 
shows the slow release behaviour of IBU from polyethylene glycol hydroxyethyl amide (PEG-
HEA) due to the hydrolysis of amide bond between IBU and hydroxyl ethyl amide [51].   
 
Figure 5-8 The cumulative release of LVF from: PVA/LVF, PVA-CS/ LVF and PVA/Conjugated CS-LVF 
electrospun mats (pH 7.4 and pH 9.0). 
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5.5 Conclusion 
This Chapter describes a new composite nanofibrous material for achieving sustained drug 
release. The novel nanofibrous material combines covalently binding the carboxyl group of the 
LVF to the amine group of CS through the formation of a amide bond and confining the 
conjugated LVF into PVA nanofibres using electrospinning. Such an approach significantly 
reduced the burst release of the drug from uniform PVA nanofibres after 8 h and led to a 
sustained release over 72 h in phosphate buffer. The findings show that chemically binding of 
a drug to the polymer backbone of chitosan and distribution of the conjugated polymer in the 
nanofibres provides an effective means of achieving sustained drug release efficacy due to 
cleavable bond between drug and nanocarrier that can be cleaved by hydrolysis attack in buffer 
solution. Approximately 50% of the drug was delivered over 72 h. 
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CONCLUSION AND SUGGESTIONS FOR 
FUTURE RESEARCH 
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6.1 Summary 
The purpose of this thesis was to investigate mechanisms that can slow the release of a drug 
from nanofibres. Different composite nanofibrous mats were designed and fabricated and the 
release of the drug monitored. The research originated from the idea that the drug release profile 
of nanofibres could be improved by physical and chemical approaches. The objectives of the 
thesis have been successfully accomplished by slowing down the release profiles in order to 
reduce the burst release from conventional uniform biodegradable nanofibres and films.   
The followings are the main conclusions obtained from this research: 
 The first approach to achieve the slow release in this research has been carried out by 
physically adsorbing the drug into mesoporous silica nanoparticles and confining them 
in the core section of the core-shell nanofibres using core-shell electrospinning. The 
LVF-MSN complexes were characterized by different methods such as FTIR and BET 
analysis to prove the presence of the drug in the mesoporous structure of MSN. This 
combination method significantly reduced the burst release of the LVF from 
conventional biodegradable nanofibres. The slow release of drug from core-shell 
PCL/LVF-MSN composite nanofibres was achieved and the sustained release was 
followed over a two week period. As a result, the composite electrospun nanofibres 
exhibited strong antimicrobial activity even after they had been soaked in a phosphate 
buffer for 14 days. The findings show that physical adsorption of a drug on a 
nanostructure and distribution of the nanostructure in the core-shell nanofibres provides 
effective means to achieving sustained drug release efficacy. 
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 Besides physically adsorbing drug on to the nanoparticles, covalently binding the drug 
to nanoparticles was shown to have an important role in reducing the burst release of 
drug. This approach includes conjugating the drug to nanoparticles. The LVF-MSN 
conjugation were fabricated by covalently binding the carboxyl group of the LVF to a 
thiol functionalised MSN through the formation of a thioester bond.  The conjugated 
complexes were characterized by IR and 13C CP MAS to confirm the successful covalent 
bond formation between the LVF and MSN. The release profile of LVF from the 
conjugated MSN showed slower release in pH 7.4 buffer solution than in pH 9.0 due to 
faster hydrolysis of thioester bond in alkaline solutions. The conjugated MSN then were 
fabricated into the nanofibres using electrospinning. This approach significantly reduced 
the burst release of the drug as compared to that from the control unconjugated 
electrospun nanofibres. Sustained release was achieved over 2 weeks in phosphate 
buffer. The results show that chemically binding of a drug to a nanocarrier and 
distributing drug conjugated nanocarriers in the nanofibres is an effective strategy to 
achieve sustained drug release via a cleavable thioester bond between a suitable drug 
and suitable nanocarrier that can be cleaved by hydrolysis attack at suitable pHs. 
 The final approach in this thesis is about reducing the burst release of highly soluble 
PVA nanofibres. This approach including conjugating drug to another polymer as a 
carrier of drug and then blending conjugated polymer with PVA nanofibres via 
electrospinning. LVF was covalently bound to the amine group of CS via amide bond. 
The conjugation of CS-LVF was characterized and confirmed by FTIR, DSC, TGA 
and H-NMR. The conjugated CS-LVF was blended with PVA solution and the 
composite nanofibres were electrospun. The results showed that the burst release of 
LVF in PVA/LVF and PVA-CS/LVF considerably reduced in PVA/conjugated CS-
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LVF. The slower release profile was achieved to the cleavable amide bond between 
LVF and CS that can be hydrolysed. The results showed that release of LVF is pH 
dependant; faster hydrolysis of amide bonds occurred in acidic buffered solution (pH 
5.0) consequently resulting in a faster LVF release profile. 
 
6.2 Further Work  
Electrospinning is a promising method to fabricate a drug loaded composite membrane. 
However, there are still limitations in the electrospinning of nanofibres that requires 
improvement. Starting from electrospun composite mats investigated in this thesis, there are 
issues to be considered. Therefore, some suggestions are proposed for future work. 
1. At the current stage, the biodegradable polymers studied in this thesis are all “bulk 
eroding” polymers, where the polymer degradation and erosion occurs through the bulk 
of the polymers. This issue leads to a fast release of drug molecules from the matrix. 
There is another class of biodegradable polymers which are called “surface eroding” 
polymers such as poly-anhydrides. The degradation and erosion in this class occurs via 
the layer by layer erosion of the surface of the polymer as new surface is exposed to an 
environment. This class of polymers is very expensive to synthesis so there are few 
studies reported on them. Employing polyanhydride as the main structure of the 
nanofibres matrix should be very promising in controlling the release of drug from the 
nanocarriers.  
2. The electrospinning technique has room to improve specially co-axial electrospinning. 
There is a new “burn” electrospinning technique called tri-axial electrospinning. This 
technique can fabricate up to three layers in one nanofibre which can be designed as a 
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new nanofibrous drug delivery systems to achieve even longer drug release. This 
technique can contain the combination of different biodegradable polymers in each 
layer to achieve longer release profiles of one or more drugs simultaneously. 
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